BSE Healthcare

SUVEN PHARMACEUTICALS: CO COMPLETED THE ACQUISITION OF 56% EQUITY STAKE IN NJ BIO, INC. FOR USD 64.4 MILLION

AUROBINDO PHARMA: CO UNIT CURATEQ BIOLOGICS RECEIVES APPROVAL FOR ONCOLOGY BIOSIMILAR BEVQOLVA FROM UK’S MHRA

FORTIS HEALTHCARE: CO ACQUIRES 7.61% EQUITY STAKE IN AGILUS DIAGNOSTICS -- DEAL FOR 4.29B RUPEES

LAURUS LAB: CO SAYS EIGHT ROADS VENTURES AND F-PRIME CAPITAL (“INVESTORS”) HAVE TOGETHER INVESTED RUPEES 120 CRORES IN LAURUS BIO PRIVATE LIMITED, A SUBSIDIARY OF CO

SHILPA MEDICARE: CO RECEIVED THE GMP CERTIFICATION AFTER SUCCESSFUL CLOSURE OF THE INSPECTION

MAX HEALTHCARE INSTITUTE LTD: RS. 59.46 CRORES NSE BLOCK TRADE; FOR ~ 503878 SHARES, AT RS. 1180.00

ALEMBIC PHARMA: CO RECEIVES USFDA FINAL APPROVAL FOR DIVALPROEX SODIUM DELAYEDRELEASE CAPSULES USP, 125 MG WITH SALES OF USD 61.1M

ZYDUS LIFESCIENCES LTD: Rs. 49.69 Crores NSE Block Trade; for ~ 503886 Shares, at Rs. 986.10

ZYDUS LIFE: CO RECEIVES FINAL APPROVAL FROM USFDA FOR LIDOCAINE AND PRILOCAINE CREAM USP -- LIDOCAINE AND PRILOCAINE CREAM HAD ANNUAL SALES OF USD 22M IN US

MANKIND PHARMA LTD: Rs. 21.02 Crores NSE Block Trade; for ~ 74523 Shares, at Rs. 2820.55

IOL CHEMICALS AND PHARMA: BOARD MEETING ON DEC 27 TO CONSIDER SHARE SPLIT (CORRECTION)

YATHARTH HOSPITAL: CO BOARD AUTHORIZES OPENING OF QIP -- FLOOR PRICE FOR QIP ISSUE 626.18 RUPEES/SHARE

LUPIN: CO GOT APPROVAL FROM U.S. FDA FOR ITS ANDA FOR EMTRICITABINE, TENOFOVIR ALAFENAMIDE TABLETS 200 MG/25 MG, TO MARKET A GENERIC EQUIVALENT OF DESCOVY® TABLETS, 200 MG/25 MG OF GILEAD SCIENCES, INC. -- LUPIN IS ONE OF THE FIRST ANDA APPLICANTS AND IS ELIGIBLE FOR 180 DAYS OF SHARED GENERIC EXCLUSIVITY

GLENMARK PHARMA: CO ACQUIRES 34% STAKE IN O2 RENEWABLE ENERGY XXIV PVT LTD -- ENTITY BEING ACQUIRED BELONGS TO GENERATION AND TRANSMISSION OF SOLAR ENERGY AND OTHER SOURCES OF RENEWABLE ENERGY

IOL CHEMICALS AND PHARMA: BOARD MEETING ON DEC 28 TO CONSIDER SHARE SPLIT

FDC: CO HAS RECEIVED APPROVAL FROM US FDA FOR THE CO’S ABBREVIATED NEW DRUG APPLICATION (ANDA) FOR CEFIXIME 400 MG TABLETS

IPCA LABORATORIES LTD: RS. 113.72 CRORES NSE BLOCK TRADE; FOR ~ 743560 SHARES, AT RS. 1529.40

IPCA LABORATORIES LTD: RS. 675.18 CRORES BSE BLOCK TRADE; FOR ~ 4440830 SHARES, AT RS. 1520.40

TORRENT PHARMACEUTICALS LTD: Rs. 19.38 Crores NSE Block Trade; for ~ 57033 Shares, at Rs. 3398.70

CIPLA: CITI SAYS GATTEX IS A USD 700M PRODUCT IN THE US AND IF GENERIC APPROVAL COMES THROUGH, IT COULD BE A USD 80-140M ANNUAL REVENUE PRODUCT FOR CIPLA

CIPLA: CITI NOTES SAYS GATTEX (TUDUGLUTIDE) CAN BE A BIG PRODUCT – PIPELINE VISIBILITY IMPROVES BEYOND REVLIMID

ALEMBIC PHARMA: CO ISSUES CORPORATE GUARANTEE OF $10M IN FAVOUR OF HSBC BANK, CHILE FOR CHILE-BASED ARM ALEMBIC PHARMACEUTICALS SPA

GLENMARK LIFE SCIENCES: MINISTRY OF CORPORATE AFFAIRS (MCA) HAS APPROVED CHANGE IN CO’S NAME TO ALIVUS LIFE SCIENCES W.E.F. DECEMBER 17, 2024

ALKEM LAB: CO & UNIT ENZENE BIOSCIENCES HAVE AGREED TO INVEST 26% EQUITY IN SUNSURE SOLARPARK FOR RENEWABLE ENERGY GENERATION, TOTALING RS. 1.95 CRORE

AUROBINDO PHARMA: CO SAYS COMPLETION OF US FDA INSPECTION AT UNIT V OF APITORIA PHARMA -- INSPECTION CLOSED WITH 2 OBSERVATIONS

SURPIYA LIFESCIENCES: CO SAYS EXPANSION BOOSTS OUR LOTE PARSHURAM CAPACITY BY OVER 55%, INCREASING IT FROM 597 KLPD TO 932 KLPD

SUPRIYA LIFESCIENCE: CO DEVELOPED WITH AN INVESTMENT OF APPROXIMATELY ₹125 CRORE

SUPRIYA LIFESCIENCE: CO INAUGURATES STATE-OF-THE-ART MODULE E PRODUCƟON BLOCK AT LOTE PARSHURAM, MAHARASHTRA

INDOCO REMEDIES: COS GOA FACILITY ACCOUNTS FOR 65-70% OF THE COS TOTAL REVENUE

INDOCO REMEDIES: COS GOA FACILITY HAS RECEIVED A WARNING LETTER FROM THE USFDA

GRANULES INDIA: CO ANNOUNCES FDA APPROVAL FOR ADHD TREATMENT, ADDRESSING DRUG SHORTAGES IN THE U.S.

GLOBAL HEALTH LTD: RS. 57.45 CRORES NSE BLOCK TRADE; FOR ~ 520667 SHARES, AT RS. 1103.35

SUN PHARMA ADVANCED RESEARCH: CO UPDATES REGARDING ASSET DEVELOPED IN THREE-YEAR PARTNERSHIP BETWEEN CO AND UCSF -- CO TO RECEIVE 55% EQUITY IN TILLER THERAPEUTICS

SUN PHARMA ADVANCED RESEARCH: CO ANNOUNCES SIGNING OF BINDING LOI WITH UCSF AND TILLER THERAPEUTICS FOR PRE-CLINICAL ONCOLOGY ASSET AND ASSOCIATED INTELLECTUAL PROPERTY

MANKIND PHARMA: CO APPROVES RUPEES 3,000 CR FUNDRAISE VIA QIP AT FLOOR PRICE RUPEES 2,616.55/SHARE

MANKIND PHARMA: CO TO LAUNCH UP TO RS 3,000-CRORE QIP SHORTLY - MONEYCONTROL

CAPLIN POINT: CAPLIN STERILES GETS USFDA APPROVAL FOR DIFLUPREDNATE OPHTHALMIC EMULSION -- US SALES OF APPROXIMATELY USD 21M

ZYDUS LIFESCIENCES: DISINVESTMENT OF EQUITY STAKE OF MYLAB DISCOVERY SOLUTIONS -- CO UNIT ACQUIRED 6.5% STAKE IN MYLAB FOR 106 CR RUPEES

JB CHEMICALS & PHARMACEUTICALS LTD: Rs. 27.87 Crores NSE Block Trade; for ~ 150336 Shares, at Rs. 1853.65

WOCKHARDT LTD: Rs. 29.08 Crores NSE Block Trade; for ~ 190063 Shares, at Rs. 1530.00

WOCKHARDT: ZAYNICH ENABLES US CANCER PATIENT UNDERGO SUCCESSFUL LIVER TRANSPLANT AND RESUME CHEMOTHERAPY BY ERADICATING DUAL EXTREME-DRUG RESISTANT GRAM NEGATIVE PATHOGENS

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA LAUNCHES LACOSAMIDE ORAL SOLUTION -- THIS SOLUTIONS HAS ACHIEVED ANNUAL SALES OF APPROX USD 57M (CORRECTION)

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA LAUNCHES LACOSAMIDE ORAL SOLUTION -- THIS SOLUTIONS HAS US SALES OF USD 57M

BIOCON LTD: EMA’S CHMP RECOMMENDS APPROVAL OF BIOCON BIOLOGICS’ YESINTEK, BIOSIMILAR TO J&J’S STELARA

AUROBINDO PHARMA: CURATEQ BIOLOGICS RECEIVES POSITIVE OPINION FOR BIOSIMILAR ZEFYLTI -- EUROPEAN AGENCY ADOPTS POSITIVE OPINION FOR CURATEQS BIOSIMILAR ZEFYLTI

LUPIN: CO SAYS TRADEMARK RIGHTS TO BE TRANSFERRED TO LUPIN BY MARCH

LUPIN: CO ACQUIRES 3 TRADEMARKS FROM BOEHRINGER INGELHEIM TO STRENGTHEN DIABETES PORTFOLIO -- GIBTULIO®, GIBTULIO MET® AND AJADUO® ARE KEY COMPONENTS FOR DIABETES TREATMENT

NEULAND LABS: CO COMPLETES FINAL TRANSFER OF NANAKRAMGUDA PROPERTY FOR RUPEES 23.45 CR

NEULAND LAB: CO UPDATE ON FINAL TRANSFER OF PART OF NANAKRAMGUDA PROPERTY

MAX HEALTHCARE: Rs 18.91cr NSE Block Trade; for ~160561 shares, at Rs 1177.85

GLENMARK PHARMA: CO ISSUED A STRING OF RECALLS FOR PILLS THAT DIDN’T DISSOLVE PROPERLY. IN ONE CASE, THE CO SAID THE PROBLEM COULD BE DEADLY

GLENMARK PHARMA: LIKELY NEGATIVE USFDA ACTION INDICATED AT KEY FACILITY

ASTER DM HEALTHCARE: CO INVEST 4.9M USD IN AFFINITY

CONCORD BIOTECH: CO HAS MADE INVESTMENT OF USD 1M IN COMPULSORILY CONVERTIBLE NOTES OF PALVELLA THERAPEUTICS, INC

DR REDDYS: CO POSTED POOR EXPORT DATA FOR THE MONTH OF NOVEMBER

NATCO PHARMA: CO REPORTS STRONG EXPORTS DATA-- NATCO EXPORTS UP ~2X YOY

NEULAND : CO REPORTS STRONG EXPORTS DATA-- NEULAND EXPORTS UP 3X YOY IN NOVEMBER

INDEGENE: KOTAK UPGRADE TO BUY FROM ADD EARLIER, TARGET 730/SHARE

NEULAND LAB: RS 778.57CR NSE BLOCK TRADE; FOR ~489667 SHARES, AT RS 15900 (AT OPEN)

STRIDES PHARMA: CO COMPLETES ALLOTMENT OF EQUITY SHARES TO SHAREHOLDERS UNDER SCHEME OF ARRANGEMENT -- CO SAYS AS PER THE SCHEME, ONESOURCE ALLOTTED ONE EQUITY SHARE OF RE. 1 EACH FOR EVERY TWO EQUITY SHARES OF RS. 10 HELD BY STRIDES SHAREHOLDERS

MOREPEN LABORATORIES: DR. MOREPEN TARGETING REVENUE OF 300M RUPEES IN FIRST YEAR FROM LIGHTLIFE -- DR. MOREPEN HAS GOAL OF 1B RUPEES REV OVER NEXT THREE YEARS FROM LIGHTLIFE - RTRS

GLAND PHARMA: CO HAS RECEIVED APPROVAL FROM THE USFDA FOR PHYTONADIONE INJECTABLE EMULSION USP, 10 MG/ML SINGLE DOSE AMPULES -- CO EXPECTS TO LAUNCH THIS PRODUCT THROUGH ITS MARKETING PARTNERS IN THE NEAR FUTURE -- ACCORDING TO IQVIA, THE PRODUCT HAD US SALES OF APPROXIMATELY USD 15M FOR THE TWELVE MONTHS ENDING SEPT 2024

AMI ORGANICS: CO APPROVED ENHANCEMENT IN CAPITAL EXPENDITURE UPTO 1.77B RUPEES -- CAPEX FOR BROWNFIELD PROJECT OF ELECTROLYTES ADDITIVES PRODUCTS

CIPLA: MANNKIND CORP - CENTRAL DRUGS STANDARD CONTROL ORGANISATION (CDSCO) IN INDIA HAS APPROVED AFREZZA INHALATION POWDER IN ADULTS -- MANNKIND CORP - EXPECTS TO SHIP PRODUCT FOR CIPLA BY END OF 2025 - RTRS

AUROBINDO PHARMA: CO UNIT THERANYM BIOLOGICS, CEASES TO BE A WHOLLY OWNED SUBSIDIARY FOLLOWING A 2% STAKE ALLOTMENT TO DR. SATAKARNI MAKKAPATI VIA PREFERENTIAL ISSUE

KRSNAA DIAGNOSTICS: CO TO MEET ABAKKUS ASSET MANAGEMENT ON DEC 13 -- ABAKKUS ASSET MANAGEMENT IS OWNED BY SUNIL SINGHANIA

DIVIS LABORATORIES LTD: Rs. 40.38 Crores NSE Block Trade; for ~ 68322 Shares, at Rs. 5910.55

TORRENT PHARMACEUTICALS LTD: Rs. 25.41 Crores NSE Block Trade; for ~ 75067 Shares, at Rs. 3385.00

ALEMBIC PHARMACEUTICALS: CO PASSES ANVISA (BRAZIL) GMP AUDIT FOR ITS API-II FACILITY AT PANELAV

MAX HEALTHCARE INSTITUTE LTD: Rs. 23.05 Crores NSE Block Trade; for ~ 204211 Shares, at Rs. 1128.55

MAX HEALTHCARE INSTITUTE LTD: RS. 67.74 CRORES NSE BLOCK TRADE; FOR ~ 600726 SHARES, AT RS. 1127.70

CIPLA LTD: Rs. 44.40 Crores NSE Block Trade; for ~ 303589 Shares, at Rs. 1462.60

IPCA LAB: CO RECORDS HIGHEST GROWTH AMONGST PHARMA COS AS PER NOVEMBER IPM DATA

MOREPEN LABORATORIES: DR. MOREPEN LAUNCHES LIGHTLIFE - SCIENCE-BACKED HOLISTIC WEIGHT MANAGEMENT PROGRAM

BIOCON: CO SELLS 8M EQUITY SHARES OF SYNGENE INTERNATIONAL THROUGH BLOCK DEAL -- SHAREHOLDING IN SYNGENE NOW AT 52.46%; CO RECEIVES APPROXIMATELY 6.86B RUPEES FROM SALE

ALKEM LABS: CO SAYS NET-WORTH OF TRADE GENERIC BUSINESS OF THE CO AS ON MARCH 31, 2024, WAS ABOUT RS.519 CR -- CONSIDERATION EXPECTED TO BE UP TO RS. 750 CR

ALKEM LABS: CO GETS APPROVAL TO TRANSFER ITS TRADE GENERICS BUSINESS TO ALKEM WELLNESS

SYNGENE INTERNATIONAL: RS 686.51CR BSE BLOCK TRADE; FOR ~8004496 SHARES, AT RS 857.65

GLENMARK PHARMA: ICHNOS GLENMARK INNOVATION PRESENTS FIRST CLINICAL DATA FROM PHASE 1 STUDY OF TRISPECIFIC TREAT™ ANTIBODY, ISB 2001, SHOWING HIGH OVERALL RESPONSE RATE WITH DURABLE RESPONSES AND FAVORABLE SAFETY PROFILE IN PATIENTS WITH HEAVILY PRETREATED MULTIPLE MYELOMA

METROPOLIS HEALTHCARE: CO TO ACQUIRE 100% STAKE IN CORE DIAGNOSTICS FOR 2.47B RUPEES -- ENTITY BEING ACQUIRED BELONGS TO DIAGNOSTIC SECTOR

SUPRIYA LIFESCIENCE: CO IS THE FIRST FIRM IN BRAZIL TO HAVE RECEIVED REGULATORY PERMISSION FOR THIS HIGHLY SPECIALISED PHARMACEUTICAL

SUPRIYA LIFESCIENCE: CO EXPANDS GLOBAL FOOTPRINT WITH ESKETAMINE HYDROCHLORIDE APPROVAL & ATORVASTATIN PATENT FILING

CIPLA LTD: RS. 59.57 CRORES NSE BLOCK TRADE; FOR ~ 404695 SHARES, AT RS. 1471.95

LAURUS LABS LTD: Rs. 28.80 Crores NSE Block Trade; for ~ 504239 Shares, at Rs. 571.20

BIOCON: NOVO TO CUT LIST PRICES FOR INSULIN ASPART (FIASP) BY 75% FROM 1 JAN 2026

BIOCON: CO HAS RECEIVED AN EIR WITH A VOLUNTARY ACTION INDICATED STATUS FROM US FDA, FOR OUR API FACILITY AT BENGALURU, KARNATAKA. INSPECTION CONDUCTED BY THE AGENCY BETWEEN THE 23RD TO 27TH OF SEPT

KRSNAA DIAGNOSTICS: COS ACQUISITION OF 10% STAKE IN APULKI HEALTHCARE SPV

NARAYANA HRUDAYALAYA: CO UNIT INFUSES USD 1.5M IN CAYMAN INTEGRATED HEALTHCARE LIMITED FOR WORKING CAPITAL NEEDS

SUVEN PHARMA: CO ACQUIRES 56% STAKE IN NJ BIO, INC. FOR USD 64.4M

ALEMBIC PHARMA: CO DISSOLVES SIX STEP-DOWN SUBSIDIARIES, NAMELY OKNER REALTY LLC, ALEMBIC LABS LLC, ALNOVA PHARMACEUTICALS SA, DAHLIA THERAPEUTICS SA, GENIUS LLC & ALEMBIC MAMI SPA

LAURUS LABS: DEAL WITH EIGHT ROADS VENTURES AND F-PRIME CAPITAL FOR INVESTMENT OF 1.2B RUPEES; SHAREHOLDING OF INVESTORS AND CO IN UNIT SHALL BE 13.73% AND 74.64%, RESPECTIVELY -- CO AND INVESTORS WILL HAVE RIGHT TO INVEST ADDITIONAL UP TO 350M RUPEES IN UNIT

LAURUS LABS: CO APPROVED INVESTMENT OF 400M RUPEES IN LAURUS BIO -- CO APPROVED EXECUTION OF AGREEMENTS WITH EIGHT ROADS VENTURES AND F-PRIME CAPITAL

TORRENT PHARMACEUTICALS LTD: Rs. 40.37 Crores NSE Block Trade; for ~ 120316 Shares, at Rs. 3355.70

GPT HEALTHCARE: CO SIGNS MOU FOR CONSTRUCTION OF HOSPITAL IN JAMSHEDPUR

KRISHNA INSTITUTE OF MEDICAL SCIENCES: CO ACQUIRES ADDITIONAL 3.00% STAKE IN ARUNODAYA HOSPITALS -- DEAL FOR 22.5 MLN RUPEES

AUROBINDO PHARMA LIMITED: CO US SALES IS USD 106M

AUROBINDO PHARMA LIMITED: CO UNIT WINS USFDA APPROVAL FOR PAZOPANIB TABLETS, 200 MG

MAX HEALTHCARE INSTITUTE LTD: RS. 65.55 CRORES NSE BLOCK TRADE; FOR ~ 601383 SHARES, AT RS. 1090.00

DIVIS LABS: CO SAYS CAN NOT COMMENT ON PATENT LAWSUITS OF BIG PHARMA COMPANIES AND ITS IMPACT

METROPOLIS HEALTHCARE: CO TO CONSIDER PREFERENTIAL ISSUE OF EQUITY SHARES ON DEC 9

TORRENT PHARMA: CO ENTERS INTO AN AGREEMENT WITH BOEHRINGER INGELHEIM TO ACQUIRE 3 ANTI-DIABETES BRANDS -- THE ACQUISITION FURTHER STRENGTHENS TORRENT’S EXISTING DIABETES CARE PORTFOLIO AND ITS PRESENCE IN THE ORAL ANTI DIABETIC MARKET

IPCA LABORATORIES: CO ANNOUNCES THE VOLUNTARY CLOSURE OF ITS DEFUNCT WHOLLY-OWNED SUBSIDIARY, IPCA PHARMACEUTICALS LTD SA DE CV, MEXICO, WITH NO IMPACT ON ITS BUSINESS OR FINANCIALS.

DIVIS LABORATORIES LTD: RS. 62.58 CRORES NSE BLOCK TRADE; FOR ~ 100285 SHARES, AT RS. 6240.70

ALEMBIC PHARMA: CO ANNOUNCES USFDA TENTATIVE APPROVAL FOR OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION USP, 0.7% (OTC) -- THIS SOLUTION HAS US SALES OF USD 22M

AUROBINDO PHARMA: CO CLARIFIES ON THE NEWS APPEARED IN THE MEDIA ON KAKINADA SEAPORT & KAKINADA SEZ

LAURUS LABS: SETBACK FOR INDIAN CDMO SPACE -- FATE OF THE US BIOSECURE ACT WITH EACH PASSING DAY THE PROBABILITY OF BIOSECURE ACT PASSING BY THE US SENATE IS REDUCING - SALES NOTE

SYNGENE: SETBACK FOR INDIAN CDMO SPACE -- FATE OF THE US BIOSECURE ACT WITH EACH PASSING DAY THE PROBABILITY OF BIOSECURE ACT PASSING BY THE US SENATE IS REDUCING - SALES NOTE

DIVIS LABS: SETBACK FOR INDIAN CDMO SPACE, SALES NOTE SAYS ON FATE OF THE US BIOSECURE ACT THAT IF THE BIOSECURE ACT DOESN’T CLEAR BY DEC 20 IT WOULD BE A DEAD BILL

SYNGENE: SETBACK FOR INDIAN CDMO SPACE -- FATE OF THE US BIOSECURE ACT WITH EACH PASSING DAY THE PROBABILITY OF BIOSECURE ACT PASSING BY THE US SENATE IS REDUCING

AUROBINDO PHARMA: ANDHRA PRADESH CID BEGINS PROBE INTO ALLEGED FORCIBLE ACQUISITION BY AURBINDO PHARMA GROUP IN 2020 - SOUTH FIRST

MAX HEALTHCARE: CO HAS ISSUED A CORPORATE GUARANTEE OF RUPEES 1,000 CR TO AXIS BANK LIMITED TO SECURE A LONG-TERM LOAN FOR ITS UNIT, JAYPEE HEALTHCARE LIMITED

THYROCARE TECHNOLOGIES: CO HAS MADE ANOTHER TRANCHE OF EQUITY INVESTMENT OF USD 100,000 IN THYROCARE LABORATORIES (TANZANIA) LIMITED

AUROBINDO PHARMA: CO IS BIGGEST BENEFICIARY OF GRANULES SETBACK - INVESTEC REPORT

MANKIND PHARMA LTD: RS. 67.10 CRORES NSE BLOCK TRADE; FOR ~ 262309 SHARES, AT RS. 2557.95

GRANULES: GAGILLAPUR FACILITY IS CRUCIAL TO THE COMPANYS OPERATIONS, CONTRIBUTING OVER 70% OF OVERALL REVENUE AS OF THE JUNE QUARTER

GRANULES INDIA LTD: CO US FDA HAS CLASSIFIED THE INSPECTION AS “OFFICIAL ACTION INDICATED” (OAI) -- CO HAS RESPONDED TO ALL THE OBSERVATIONS ISSUED BY THE US FDA

GRANULES INDIA: CO HAS RESPONDED TO ALL THE OBSERVATIONS ISSUED BY THE US FDA

FORTIS HEALTHCARE LTD: Rs. 21.41 Crores NSE Block Trade; for ~ 305422 Shares, at Rs. 701.10

FORTIS HEALTHCARE LTD: RS. 106.45 CRORES NSE BLOCK TRADE; FOR ~ 1518790 SHARES, AT RS. 700.90

APOLLO HOSPITALS ENTERPRISE LTD: Rs. 48.10 Crores NSE Block Trade; for ~ 67830 Shares, at Rs. 7091.30

GLAND PHARMA: CO RECEIVES APPROVAL FROM THE UNITED STATES FOOD AND DRUG ADMINISTRATION (US FDA) FOR LATANOPROST OPHTHALMIC SOLUTION, 0.005% (2.5 ML

INDEGENE LTD: RS. 374.62 CRORES NSE BLOCK TRADE; FOR ~ 5993928 SHARES, AT RS. 625.00

INDEGENE LTD: RS. 184.23 CRORES NSE BLOCK TRADE; FOR ~ 2937501 SHARES, AT RS. 627.15

INDEGENE: CA DAWN LIKELY TO SELL 2.9% STAKE OF INDEGENE VIA BLOCK DEALS, FLOOR PRICE AT ₹615/SH - CNBCTV18, CITING SOURCES

INDOCO REMEDIES: CO WILL CONTINUE TO SUPPLY ALL PRODUCTS UNDER EXISTING B2B PARTNERSHIP TO CLIENTS

INDOCO REMEDIES: CO ENTERS INTO A STRATEGIC DISTRIBUTION PARTNERSHIP WITH CLARITY PHARMA, UK -- CO WILL LAUNCH AROUND 20 PRODUCTS OVER 18 MONTHS THROUGH CLARITY PHARMA IN UK

BIOCON: U.S.FDA APPROVES BIOCON BIOLOGICS’ YESINTEK™, BMAB 1200 BIOSIMILAR TO J&JS STELARA

NARAYANA HRUDAYALAY: CO BOARD APPROVES AMALGAMATION SCHEME OF MERIDIAN MEDICAL RESEARCH & HOSPITAL INTO CO

NARAYANA HRUDAYALAYA: NARAYANA HEALTH CONFIRMS NO INTENTION TO MAKE OFFER FOR SPIRE -- CO CLARIFIES CO EVALUATES STRATEGIC OPPORTUNITIES ON ONGOING BASIS

ASTER DM HEALTHCARE: CO SAYS MERGED ENTITY WILL BE JOINTLY CONTROLLED BY ASTER PROMOTERS AND BLACKSTONE, HOLDING 24.0% AND 30.7% OWNERSHIP RESPECTIVELY

ASTER DM HEALTHCARE: TRANSACTION VALUES ASTER AT 36.6X FY24 ADJUSTED POST INDAS EV/ EBITDA, WHICH IS 45% HIGHER THAN THE MULTIPLE ASCRIBED TO QCIL I.E. 25.2X FY24 ADJUSTED POST INDAS EV/ EBITDA -- BASED ON THE AGREED SWAP RATIO, ASTER SHAREHOLDERS WILL HOLD 57.3% AND QCIL SHAREHOLDERS WILL HOLD 42.7% IN THE MERGED ENTITY

ASTER DM HEALTHCARE: ASTER AND BLACKSTONE-BACKED QUALITY CARE TO MERGE AND CREATE ONE OF THE TOP 3 HOSPITAL CHAINS IN INDIA WITH 10,150+ BEDS -- CO AND QUALITY CARE INDIA LIMITED HAVE SIGNED DEFINITIVE AGREEMENTS TO MERGE, SUBJECT TO REGULATORY, CORPORATE AND SHAREHOLDERS’ APPROVALS

ASTER DM HEALTHCARE: CO APPROVED SCHEME OF AMALGAMATION BETWEEN CO AND QCIL -- CO TO ACQUIRE 19M SHARES OF QCIL AT 445.8 RUPEES PER SHARE

CIPLA LTD: RS. 58.84 CRORES NSE BLOCK TRADE; FOR ~ 383555 SHARES, AT RS. 1534.15

MAX HEALTHCARE INSTITUTE LTD: RS. 53.99 CRORES NSE BLOCK TRADE; FOR ~ 551351 SHARES, AT RS. 979.20

SIGACHI INDUSTRIES: CO SAYS THE MARKET IS POISED FOR ROBUST GROWTH, WITH PROJECTIONS REACHING USD 2.1B BY 2032

SIGACHI INDUSTRIES: CO SAYS PROPAFENONE HYDROCHLRIDE, WIDELY USED IN THE TREATMENT OF CARDIAC ARRHYTHMIAS, IS A HIGH- DEMAND API WITH A CURRENT GLOBAL MARKET SIZE OF USD 1.2B

SIGACHI INDUSTRIES: CO SAYS ACHIEVING THE CERTIFICATE OF SUITABILITY FOR THIS API WILL ENABLE THE CO TO EXPORT THIS PRODUCT IN EUROPE AND OTHER CEP ACCEPTING COUNTRIES

SIGACHI INDUSTRIES: CO HAS RECEIVED A COMMUNICATION FROM EUROPEAN DIRECTORATE FOR THE QUALITY OF MEDICINES & HEALTH CARE (“EDQM”) ON ITS LATEST CEP FILING SUBMISSION OF “PROPAFENONE HYDROCHLORIDE"

DIVIS LABS: CITI SAYS CO MAY ENJOY ENTRESTO WINDFALL GAINS FOR MUCH LONGER THAN EARLIER EXPECTED -- CITI SAYS DIVIS LIKELY TO EVEN SUPPLY API TO COMPETITOR

NARAYANA HRUDAYALAYA: NARAYANA HEALTH IN TALKS TO BUY STAKES IN UK-BASED SPIRE HEALTHCARE - ET

DR. REDDY’S LABORATORIES: CO LAUNCHES TORIPALIMAB IN INDIA, THE FIRST AND ONLY IMMUNO-ONCOLOGY DRUG APPROVED FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA -- COMBINATION OF TORIPALIMAB AND STANDARD OF CARE CHEMOTHERAPY HAS SHOWN A 48% REDUCTION IN RISK OF PROGRESSION OR DEATH

MAX HEALTHCARE INSTITUTE LTD: RS. 51.79 CRORES NSE BLOCK TRADE; FOR ~ 527704 SHARES, AT RS. 981.35

DR REDDYS: CO LAUNCHES TORIPALIMAB IN INDIA, THE FIRST AND ONLY IMMUNO- ONCOLOGY DRUG APPROVED FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA

NATCO PHARMA: CO SELLS LAND FOR 1.16B RUPEES

SHILPA MEDICARE: CO SAYS IMKELDI IS AN ADVANCED LIQUID FORMULATION OF IMATINIB DESIGNED TO PROVIDE DOSING ACCURACY. IMKELDI CAN HELP SLOW OR PREVENT THE GROWTH OF SPECIFIC CANCERS, INCLUDING CHRONIC MYELOID LEUKEMIA (CML) AND ACUTE LYMPHOBLASTIC LEUKEMIA

SHILPA MEDICARE: USFDA APPROVAL OF NDA IMKELDI (IMATINIB ORAL SOLUTION) FILLED BY OUR PARTNER SHORLA ONCOLOGY DEVELOPED BY OUR JV ONCOSOL LIMITED

CIPLA LTD: Rs. 37.78 Crores NSE Block Trade; for ~ 254629 Shares, at Rs. 1483.85

GRANULES: CO NET ZERO COMMITMENT VALIDATED AND APPROVED BY SCIENCE BASED TARGETS INITIATIVE

ZYDUS LIFE: CO EYES M&A, LICENSING TO BUILD ITS US SPECIALTY BUSINESS - ET

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA LAUNCHES TRAVOPROST OPHTHALMIC SOLUTION USP, (IONIC BUFFERED SOLUTION) -- THIS SOLUTION HAS ANNUAL SALES OF APPROX USD 66M

ASTER DM HEALTHCARE: CO ENTERS AGREEMENT TO ACQUIRE ADDITIONAL 13% OF PRERANA HOSPITAL

DR. REDDYS LABORATORIES: CO AND SENORES PHARMACEUTICALS, INC. ANNOUNCE THE LAUNCH OF IVERMECTIN TABLETS USP, 3 MG IN US MARKET

SHILPA MEDICARE: CO GETS INDIAN REGULATORY AUTHORITY - SEC APPROVAL FOR CONDUCTING PHASE III CLINICAL TRIALS FOR RECOMBINANT HUMAN ALBUMIN (RHA) 20%

ASTRAZENECA PHARMA: CO HAS RECEIVED PERMISSION TO IMPORT FOR SALE AND DISTRIBUTION IN FORM CT-20 FROM THE CENTRAL DRUGS STANDARD CONTROL ORGANISATION

ALKEM LAB: TODAY 3PM MSCI GLOBAL INCLUSION EXPECTED IN FLOW: $201 MILLION (RS 16.68B)

STRIDES PHARMA SCIENCE LTD: CO SUCCESSFUL COMPLETION OF FUND RAISING OF USD 95 MILLION BY ONESOURCE

NATCO PHARMA: CO SUBMITTED ANDA WITH US FDA FOR GENERIC VERSION OF EVRYSDI (RISDIPLAM) -- CO US SALES OF USD 571M

ZYDUS LIFESCIENCES: DELHI HC SETS ASIDES TEMPORARY BAN ON SALES OF SIGRIMA BY CO - NDTV PROFIT

FORTIS HEALTHCARE LTD: RS. 96.16 CRORES NSE BLOCK TRADE; FOR ~ 1409709 SHARES, AT RS. 682.10

NATCO PHARMA: CO SOLD INVESTMENT HELD IN ISCA, INC FOR $2.1M

DR. REDDY’S LABORATORIES: USFDA COMPLETED A GMP INSPECTION AT API MANUFACTURING FACILITY (CTO-2) IN BOLLARAM, HYDERABAD; INSPECTION WAS CONDUCTED FROM 13TH NOV, 2024 TO 19TH NOV, 2024 -- CO HAS BEEN ISSUED A FORM 483 WITH 7 OBSERVATIONS

STRIDES PHARMA SCIENCE: RECEIPT OF NCLT APPROVAL FOR CREATION OF ONESOURCE -- CO SAYS FOLLOWING APPROVAL, ONESOURCE WILL ADVANCE TOWARDS LISTING ITS SHARES

SHILPA MEDICARE: CO UNIT SHILPA PHARMA LIFESCIENCES, RECEIVED CEP FROM EDQM FOR API, NIFEDIPINE

THEMIS MEDICARE: CO SAYS AMALGAMATION OF GUJARAT THEMIS BIOSYN LTD WITH THEMIS MEDICARE -- TML WILL ISSUE 118 SHARES FOR EVERY 100 SHARES HELD BY IN GTBL

THEMIS MEDICARE: CO TERMINATES AGREEMENT WITH UNIT FOR API BUSINESS TRANSFER

ASTRAZENECA PHARMA INDIA: CO SAYS WILL LAUNCH BREZTRI AEROSPHERE IN JANUARY 2025 IN INDIA -- BREZTRI AEROSPHERE IS INDICATED FOR THE MAINTENANCE TREATMENT TO RELIEVE SYMPTOMS AND PREVENT EXACERBATIONS IN ADULT PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

SHILPA MEDICARE: CO UNIT SHILPA PHARMA LIFESCIENCES LTD RECEIVED CERTIFICATE OF SUITABILITY (CEP) FROM EDQM (EUROPEAN DIRECTORATE FOR THE QUALITY OF MEDICINES & HEALTHCARE) FOR API, OCTREOTIDE

ZYDUS LIFE: SC REFUSES TO GRANT INTERIM RELIEF IN BREAST CANCER DRUG CASE -- SC SENDS BACK THE CASE TO DELHI HC - CNBC TV 18

GLENMARK PHARMA: CO CFO SAYS CO TO LAUNCH THE RESPIRATORY DRUG IN NEXT 6-8 MONTHS IN US - CNBCTV18

GLENMARK PHARMA: CO CFO SAYS H2 MARGINS IS EXPECTED TO BE BETTER GIVEN THE RESPIRATORY LAUNCHES- CNBCTV1

DR REDDYS LABORATORIES LTD: Rs. 21.26 Crores NSE Block Trade; for ~ 178648 Shares, at Rs. 1190.00

BLUE JET HEALTHCARE: CO SAYS GOT CONSENT TO OPERATE TO START MANUFACTURING AT MAHAD UNIT

ARTEMIS MEDICARE SERVICES: Q2 EBITDA 423M RUPEES VS 342M (YOY) -- Q2 EBITDA MARGIN 17.50% VS 15.2% (YOY)

ARTEMIS MEDICARE SERVICES: Q2 CONS NET PROFIT 221M RUPEES VS 135M (YOY); 165M (QOQ) -- Q2 REVENUE 2.4B RUPEES VS 2.25B (YOY)

GLENMARK PHARMA: Q2 EBITDA 6B RUPEES VS 4.6B (YOY) -- Q2 EBITDA MARGIN 17.70% VS 14.63% (YOY)

GLENMARK PHARMA: Q2 REVENUE 34.3B RUPEES VS 32.1B (YOY)

GLENMARK PHARMA: Q2 CONS NET PROFIT 3.5B RUPEES VS LOSS 2B (YOY); PROFIT 3.4B (QOQ)

GUFIC BIOSCIENCES: Q2 EBITDA 386M RUPEES VS 394M (YOY) -- Q2 EBITDA MARGIN 18.92% VS 18.32% (YOY)

GUFIC BIOSCIENCES: Q2 REVENUE 2B RUPEES VS 2.15B (YOY)

GUFIC BIOSCIENCES: Q2 SL NET PROFIT 217M RUPEES VS 232M (YOY); 208.6M (QOQ)

SASTASUNDAR VENTURES: Q2 CONS NET LOSS 1.09B RUPEES VS LOSS 58M (YOY); PROFIT 315M (QOQ) -- Q2 REVENUE 2.73B RUPEES VS 3.58B (YOY)

IOL CHEM AND PHARMA: Q2 EBITDA 420M RUPEES VS 644M (YOY) -- Q2 EBITDA MARGIN 7.98% VS 11.8% (YOY)

IOL CHEM AND PHARMA: Q2 SL NET PROFIT 192M RUPEES VS 378M (YOY); 297M (QOQ) -- Q2 REVENUE 5.26B RUPEES VS 5.45B (YOY)

GPT HEALTHCARE: Q2 REVENUE 1.1B RUPEES VS 1.08B (YOY)

GPT HEALTHCARE: Q2 EBITDA 232M RUPEES VS 246M (YOY) -- Q2 EBITDA MARGIN 22.17% VS 22.78% (YOY)

GPT HEALTHCARE: Q2 SL NET PROFIT 148M RUPEES VS 135M (YOY)

GLOBAL HEALTH: Q2 REVENUE 9.6B RUPEES VS 8.4B (YOY)

GLOBAL HEALTH: Q2 EBITDA 2.28B RUPEES VS 2.1B (YOY) -- Q2 EBITDA MARGIN 23.87% VS 25.22% (YOY)

GLOBAL HEALTH: Q2 CONS NET PROFIT 1.31B RUPEES VS 1.25B (YOY)

IPCA LABORATORIES: Q2 EBITDA 4.4B RUPEES VS 3.6B (YOY) -- Q2 EBITDA MARGIN 18.7% VS 17.65% (YOY)

IPCA LABORATORIES: Q2 REVENUE 23.55B RUPEES VS 20.4B (YOY)

IPCA LABORATORIES: Q2 CONS NET PROFIT 2.3B RUPEES VS 1.45B (YOY)

LINCOLN PHARMA: Q2 REVENUE 1.61B RUPEES VS 1.56B (YOY)

LINCOLN PHARMA : Q2 EBITDA 284M RUPEES VS 311M (YOY) -- Q2 EBITDA MARGIN 17.60% VS 19.96% (YOY)

LINCOLN PHARMA : Q2 SL NET PROFIT 263M RUPEES VS 276M (YOY)

SHILPA MEDICARE: CO SAYS OLAPARIB VALIDATION IS EXPECTED TO COMPLETE IN Q4 FY25 -- TRANXEMIC ACID EXPANSION IS ON TRACK AND EXPECTED TO START PLANT VALIDATION IN Q3 FY25 AND COMMERCIAL PRODUCTION TO START IN Q4 FY25

MARKSANS PHARMA: CO IS LOOKING FOR VALUE-ACCRETIVE M&AS AND IS WORKING ON ITS NEXT STEP OF PROJECTS IN TERMS OF CAPACITY ENHANCEMENT, GREENFIELD, OR M&A -- CO IS LOOKING AT EXPANSION IN TERMS OF NEW FACILITIES, NEW BLOCKS, OR NEW CAPEX - CONCALL UPDATE

SHILPA MEDICARE: CO SAYS PLANT VALIDATION FOR TWO NEW MOLECULES MYCOPHENOLATE MOFETIL AND MYCOPHENOLATE SODIUM EXPECTED IN Q4 FY25 -- PALBOCICLIB VALIDATION IS ONGOING AND EXPECTED TO COMPLETE IN Q3 FY25

MARKSANS PHARMA: CO EXPECTS TO ACHIEVE A REVENUE MILESTONE OF RS 3,000 CR WITHIN THE NEXT TWO YEARS THROUGH EXPANDING ITS PRESENT BUSINESS, NEW PRODUCT LAUNCHES, AND ENHANCING SUPPLY FROM ITS NEW MANUFACTURING FACILITY, CO EXPECTS A STRONGER QUARTER AHEAD, DRIVEN BY IMPROVED UK NUMBERS - CONCALL UPDATE

ALKEM LABS: CO EXPECTS PRODUCTION TO BEGIN BY Q4 TO Q1 OF NEXT FINANCIAL YEAR, WITH NO SIGNIFICANT DELAY REPORTED AS OF NOW -- ANOTHER PRODUCT LAUNCH IS EXPECTED IN Q3, WHICH HAS RECEIVED CGT WITH VANITY DAYS EXCLUSIVITY - CONCALL UPDATE

ALKEM LABS: CO IS GUIDING FOR AN IMPROVEMENT IN EBITDA MARGINS BY AT LEAST 100 BASIS POINTS EVERY YEAR -- CO AIMS TO IMPROVE THE EBITDA MARGIN IN THE U.S. BUSINESS TO BE CLOSER TO THE OVERALL EBITDA MARGIN, WHICH IS EXPECTED TO BE AROUND 18.5% TO 19% - CONCALL UPDATE

ALKEM LABS: CO IS MAINTAINING ITS OVERALL GROWTH GUIDANCE OF AROUND 8% TO 9% FOR THE DOMESTIC MARKET -- CO EXPECTS MID-SINGLE DIGIT KIND OF GROWTH ON THE TOP-LINE - CONCALL UPDATE

DISHMAN CARBOGEN AMCIS: Q2 EBITDA 1.47B RUPEES VS 610M (YOY) -- Q2 EBITDA MARGIN 18.63% VS 10.4% (YOY)

DISHMAN CARBOGEN AMCIS: Q2 CONS NET PROFIT 331M RUPEES VS LOSS 409M (YOY) -- Q2 REVENUE 7.89B RUPEES VS 5.8B (YOY)

CIPLA: CO SAYS USFDA HAS CONDUCTED AN INSPECTION AT THE CO’S MANUFACTURING FACILITY IN VIRGONAGAR, BENGALURU FROM 7TH - 13TH NOV 2024 -- CO SAYS ON CONCLUSION OF THE INSPECTION, CO RECEIVED 8 (EIGHT) OBSERVATIONS IN FORM 483

SEQUENT SCIENTIFIC: Q2 EBITDA 391M RUPEES VS 232M (YOY) -- Q2 EBITDA MARGIN 10.60% VS 6.71% (YOY)

SEQUENT SCIENTIFIC: Q2 CONS NET PROFIT 26M RUPEES VS LOSS 83.8M (YOY); 65M (QOQ) -- Q2 REVENUE 3.7B RUPEES VS 3.46B (YOY)

FDC: CO SAYS USFDA HAD CONDUCTED AN INSPECTION AT CO’S MANUFACTURING FACILITY LOCATED AT BADDI, HIMACHAL PRADESH IN THE MONTH OF AUGUST 2024 -- CO HAS NOW RECEIVED THE ESTABLISHMENT INSPECTION REPORT (EIR) FROM USFDA WITH “NO OBSERVATIONS” (ZERO 483’S)

ASTRAZENECA PHARMA: Q2 EBITDA 524M RUPEES VS 528M (YOY) -- Q2 EBITDA MARGIN 12.84% VS 16.96% (YOY)

ASTRAZENECA PHARMA: Q2 SL NET PROFIT 384M RUPEES VS 524M (YOY); LOSS 118M (QOQ) -- Q2 REVENUE 4.08B RUPEES VS 3.11B (YOY)

SHILPA MEDICARE: Q2 EBITDA 860M RUPEES VS 603M (YOY) -- Q2 EBITDA MARGIN 25.01% VS 19.27% (YOY)

SHILPA MEDICARE: Q2 CONS NET PROFIT 179M RUPEES VS 16M (YOY); 141M (QOQ) -- Q2 REVENUE 3.4B RUPEES VS 3.2B (YOY)

SIGACHI INDUSTRIES: Q2 EBITDA 172M RUPEES VS 214M (YOY) -- Q2 EBITDA MARGIN 13.79% VS 21.6% (YOY)

SIGACHI INDUSTRIES: Q2 REVENUE 1.25B RUPEES VS 992M (YOY)

SIGACHI INDUSTRIES: Q2 CONS NET PROFIT 218M RUPEES VS 151M (YOY)

UNICHEM LAB (PAT): Q2 EBITDA 580M RUPEES VS 87M (YOY) -- Q2 EBITDA MARGIN 12.55% VS 2.11% (YOY)

UNICHEM LAB: Q2 REVENUE 4.6B RUPEES VS 4.2B (YOY)

UNICHEM LAB: Q2 CONS NET PROFIT 300M RUPEES VS LOSS 245M (YOY)

ALKEM LAB: H1 FY25 EBITDA MARGIN AT 21% VS FY25 GUIDANCE OF 18%

WOCKHARDT: Q2 REVENUE 8.1B RUPEES VS 7.53B (YOY)

WOCKHARDT: Q2 EBITDA 1.28B RUPEES VS 720M (YOY) -- Q2 EBITDA MARGIN 15.82% VS 9.56% (YOY)

WOCKHARDT: Q2 CONS NET LOSS 220M RUPEES VS LOSS 770M (YOY)

ALKEM LAB: US SALES FALL 22% VS EST 4% DECLINE

ALKEM LAB: Q2 REVENUE 34.1B RUPEES VS 34.4B (YOY)

ALKEM LAB: Q2 EBITDA 7.5B RUPEES VS 7.47B (YOY) -- Q2 EBITDA MARGIN 22.04% VS 21.71% (YOY)

ALKEM LAB: Q2 CONS NET PROFIT 6.9B RUPEES VS 6.2B (YOY)

KOPRAN: Q2 EBITDA 156M RUPEES VS 228M (YOY) -- Q2 EBITDA MARGIN 10.27% VS 14.96% (YOY)

KOPRAN: Q2 REVENUE 1.52B RUPEES VS 1.5B (YOY)

KOPRAN: Q2 CONS NET PROFIT 74M RUPEES VS 138M (YOY)

DIVIS LAB: EXPORTS UP 41% YOY TO $73MN COMPANY HAS ONBOARDED NEW CLIENTS FOR GLP1 EXPORTS DATA SHOWS EXPORTS TO ROCHE & ALSO CORDENPHARMA

ZYDUS LIFESCIENCES: CO IS DEVELOPING A LARGE-SCALE FERMENTATION OF PROTEIN ISOLATE OF MILK, WHICH IS AN ANIMAL-FREE DERIVED MILK PROTEIN PRODUCT WITH SIGNIFICANT ESG BENEFITS. THERE ARE NEAR-TERM OPPORTUNITIES FOR MAJOR BIG LAUNCHES IN THE US OVER THE NEXT ONE TO TWO TO THREE YEARS - CONCALL UPDATE

ZYDUS LIFESCIENCES: CO EXPECTS TO MAINTAIN THE SAME R&D EXPENSE PERCENTAGE GOING FORWARD, AT LEAST FOR THE NEAR FUTURE. FY26 GUIDANCE IN THE US EXPECTS GROWTH OVER FY25, DESPITE ETHICAL COMPETITION - CONCALL UPDATE

ZYDUS LIFESCIENCES: CO PROVIDED GUIDANCE ON R&D EXPENSE, EXPECTING IT TO BE AROUND 8% OF REVENUE FOR THE FULL FY25 -- CO SAYS FY27 AND FY28 GUIDANCE IS EXPECTED TO BE "MEANINGFULLY VERY LARGE" DUE TO LARGE OPPORTUNITIES AND DAY ONE EXCLUSIVE LAUNCHES - CONCALL UPDATE

SUVEN PHARMA: Q2 EBITDA 1.05B RUPEES VS 980M (YOY) -- Q2 EBITDA MARGIN 40.70% VS 42.40% (YOY)

SUVEN PHARMA: Q2 CONS NET PROFIT 822M RUPEES VS 796M (YOY); 608M (QOQ) -- Q2 REVENUE 2.6B RUPEES VS 2.31B (YOY)

NEULAND LABORATORIES: CO TRANSFERRED PART OF NANAKRAMGUDA PROPERTY FOR 630 MLN RUPEES

SANOFI CONSUMER HEALTHCARE INDIA: Q2 EBITDA 631M RUPEES VS 946M (YOY) -- Q2 EBITDA MARGIN 39.46% VS 44.98% (YOY)

SANOFI CONSUMER HEALTHCARE INDIA: Q2 SL NET PROFIT 450M RUPEES VS 712M (YOY); 290M (QOQ) -- Q2 REVENUE 1.6B RUPEES VS 2.1B (YOY)

AUROBINDO PHARMA: CO SAYS EUROPEAN MEDICINES AGENCY (EMA) GRANTS GOOD MANUFACTURING PRACTICE (GMP) CERTIFICATE OF COMPLIANCE TO CURATEQ BIOSIMILARS’ MANUFACTURING FACILITY IN HYDERABAD

HIKAL: Q2 EBITDA 749M RUPEES VS 575M (YOY) -- Q2 EBITDA MARGIN 16.54% VS 13.23% (YOY)

HIKAL: Q2 REVENUE 4.5B RUPEES VS 4.34B (YOY)

HIKAL: Q2 CONS NET PROFIT 183M RUPEES VS 126M (YOY)

NATCO PHARMA: Q2 REVENUE 13.7B RUPEES VS 10.3B (YOY)

NATCO PHARMA: Q2 EBITDA 8.04B RUPEES VS 4.58B (YOY) -- Q2 EBITDA MARGIN 58.66% VS 44.41% (YOY)

NATCO PHARMA: Q2 CONS NET PROFIT 6.7B RUPEES VS 3.69B (YOY)

ALEMBIC PHARMACEUTICALS: CO ANNOUNCES USFDA FINAL APPROVAL FOR IVABRADINE TABLETS, 5 MG AND 7.5 MG -- US SALES OF USD 145.3 M

SHILPA MEDICARE: CO ANNOUNCES ACCEPTANCE BY USFDA OF NDA FILED BY ITS CDMO PARTNER UNICYCIVE - FOR OXYLANTHANUM CARBONATE

MARKSANS PHARMA: CO IS FOCUSING DOUBLING REVENUE IN THE US AND NORTH AMERICA

MARKSANS PHARMA: CO SAYS HIGH GROWTH IN REVENUES AND MARGIN. AIM TO REACH REVENUE OF RS 3,000 CR IN NEXT 2 YEARS

MARKSANS PHARMA: CO MD SAYS WE ANTICIPATE STRONGER PERFORMANCE IN THE COMING QUARTERS DUE TO OUR UPCOMING NEW LAUNCHES, THE ONSET OF THE WINTER SEASON AND SCALING UP OF THE TEVA FACILITY

MARKSANS PHARMA: Q2 EBITDA 1.3B RUPEES VS 1.1B (YOY) -- Q2 EBITDA MARGIN 21.12% VS 21.46% (YOY)

MARKSANS PHARMA: Q2 REVENUE 6.4B RUPEES VS 5.3B (YOY)

MARKSANS PHARMA: Q2 CONS NET PROFIT 967M RUPEES VS 835M (YOY)

ZYDUS LIFESCIENCES: US FORMULATIONS SALES DE-GROWTH OF 21.9% (QOQ) AT USD 288M VS USD 371M (QOQ)

ZYDUS LIFESCIENCES: Q2 REVENUE 52.4B RUPEES VS 43.7B (YOY)

ZYDUS LIFESCIENCES: Q2 EBITDA 14.6B RUPEES VS 11.46B (YOY) -- Q2 EBITDA MARGIN 27.91% VS 26.23% (YOY)

ZYDUS LIFESCIENCES: Q2 CONS NET PROFIT 9.1B RUPEES VS 8B (YOY)

AUROBINDO PHARMA: ELARA ON CO, UPGRADE TO BUY FROM ACCUMULATE, TARGET PRICE AT RUPEES 1,568

AUROBINDO PHARMA: CO IS CONFIDENT IN ACHIEVING INTERNALLY TARGETED EBITDA MARGINS OF 21% TO 22% FOR FY 25 -- CO EXPECTS TO ACHIEVE BREAKEVEN IN THE PENICILLIN-G PRODUCT FACILITY BY Q4 FY 25 AND START CONTRIBUTING POSITIVELY FROM FY 26 ONWARDS - CONCALL UPDATE

ORCHID PHARMA: ORBLICEF, A DRUG PRODUCT FOR ENMETAZOBACTAM SPECIFYING COMBINATION, WAS SUCCESSFULLY LAUNCHED IN THE INDIAN MARKET DURING THE LAST WEEK OF SEPTEMBER -- CO HAS A MARKETING PARTNERSHIP WITH CIPLA, WHICH IS EXPECTED TO DRIVE SALES MOMENTUM IN THE COMING MONTHS - CONCALL UPDATE

ORCHID PHARMA: CO PRODUCT WAS COMPARED TO PIP-TAZ IN A CLINICAL TRIAL INVOLVING OVER 1,000 PATIENTS, WITH AN EFFICACY RATE OF 79% COMPARED TO 59% FOR PIP-TAZ - CONCALL UPDATE

MAX HEALTHCARE: CO PLANS TO ADD OVER 6,000 BEDS, WITH AROUND 3,500 BEDS EXPECTED BY FY28, SUPPORTED BY A SIGNIFICANT LAND BANK AND AN ESTIMATED CAPITAL OUTLAY OF RS 3,048 CRORE.

ORCHID PHARMA: Q2 REVENUE 2.2B RUPEES VS 1.99B (YOY)

ORCHID PHARMA: Q2 EBITDA 296M RUPEES VS 237M (YOY) -- Q2 EBITDA MARGIN 13.29% VS 11.92% (YOY)

ORCHID PHARMA: Q2 SL NET PROFIT 256M RUPEES VS 202M (YOY)

MOREPEN LAB: CO SAYS REVENUE AT RS 5000 CR BY 2030 & CAGR AT 20%; PAT AT 10% BY 2030

MOREPEN LABORATORIES: Q2 EBITDA 440.7M RUPEES VS 335M (YOY) -- Q2 EBITDA MARGIN 10.07% VS 7.96% (YOY)

MOREPEN LABORATORIES: Q2 REVENUE 4.4B RUPEES VS 4.2B (YOY)

MOREPEN LABORATORIES: Q2 CONS NET PROFIT 348M RUPEES VS 213M (YOY)

CONCORD BIOTECH: Q2 REVENUE 3.1B RUPEES VS 2.6B (YOY)

CONCORD BIOTECH: Q2 EBITDA 1.36B RUPEES VS 1.19B (YOY) -- Q2 EBITDA MARGIN 44.06% VS 45.43% (YOY)

CONCORD BIOTECH: Q2 SL NET PROFIT 987M RUPEES VS 845M (YOY)

APOLLO HOSPITAL: CO WITHDREW ITS 50% GMV GROWTH GUIDANCE FOR APOLLO 24/7

APOLLO HOSPITAL: COS OVERALL STRONG RESULTS BUT GUIDANCE CUT, CO LOWERED HOSPITAL MARGIN EXPANSION TARGET FROM 100-150BPS TO 50-60BPS FOR FY25

MAX HEALTHCARE INSTITUTE LTD: Rs. 21.39 Crores NSE Block Trade; for ~ 201568 Shares, at Rs. 1061.00

MAX HEALTHCARE INSTITUTE LTD: Rs. 32.36 Crores NSE Block Trade; for ~ 305042 Shares, at Rs. 1061.00

KIMS: COS EXPANSION PLANS TO ADD APPOX. 2,085 BEDS ACROSS MULTIPLE CITIES WITH RS. 1,870 - 2,010 CR CAPEX - INVESTOR PRESENTATION

BIOCON: USFDA CLASSIFIES BIOCON BIOLOGICS’ BIOCON PARK SITE IN BENGALURU AS VOLUNTARY ACTION INITIATED

ALEMBIC PHARMA: CO ANNOUNCES USFDA FINAL APPROVAL FOR DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULES USP -- THIS CAPSULES HAS US SALES OF USD 105M

KIMS: CO ENTERED INTO 15-YEAR OPERATIONS & MANAGEMENT AGREEMENT WITH INSIGNIA HEALTHCARE PVT. LTD. FOR 150-BED SUPER SPECIALTY HOSPITAL IN ANDHRA PRADESH

KRISHNA INSTITUTE OF MEDICAL SCIENCES: Q2 EBITDA 2.18B RUPEES VS 1.77B (YOY) -- Q2 EBITDA MARGIN 28% VS 27.16% (YOY)

KRISHNA INSTITUTE OF MEDICAL SCIENCES: Q2 CONS NET PROFIT 1.07B RUPEES VS 920M (YOY) -- Q2 REVENUE 7.77B RUPEES VS 6.52B (YOY)

HEALTHCARE GLOBAL ENTERPRISES: Q2 EBITDA 1.03B RUPEES VS 846M (YOY) -- Q2 EBITDA MARGIN 18.7% VS 17.42% (YOY)

HEALTHCARE GLOBAL ENTERPRISES: Q2 CONS NET PROFIT 180M RUPEES VS 136M (YOY) -- Q2 REVENUE 5.52B RUPEES VS 4.86B (YOY)

HEALTHCARE GLOBAL: CO UPDATES REGARDING TRANSFER OF DIAGNOSTIC BUSINESS TRIESTA AND PET-CT/CYCLOTRON UNIT VIA BTA TO CO UNIT, DEAL VALUED AT RUPEES 135 CR

AUROBINDO PHARMA: COS US REVENUE IN Q2FY25 INCREASED BY 2.9% YOY AND DECREASED BY 1.1% QOQ TO USD 421M, ACCOUNTING FOR 45.3% OF CONSOLIDATED REVENUE

AUROBINDO PHARMA: Q2 EBITDA 15.66B RUPEES VS 13.86B (YOY); EST 16.5B -- Q2 EBITDA MARGIN 20.1% VS 19% (YOY); EST 21%

AUROBINDO PHARMA: Q2 REVENUE 78B RUPEES VS 72.19B (YOY); EST 77.57B

AUROBINDO PHARMA: Q2 CONS NET PROFIT 8.17B RUPEES VS 7.57B (YOY); EST 9.3B

ADVANCED ENZYME TECH: Q2 EBITDA 424M RUPEES VS 513M (YOY) -- Q2 EBITDA MARGIN 29.04% VS 32.51% (YOY)

ADVANCED ENZYME TECH: Q2 CONS NET PROFIT 328M RUPEES VS 344M (YOY) -- Q2 REVENUE 1.46B RUPEES VS 1.58B (YOY)

DIVIS LABS: Q2 REVENUE 23.38B RUPEES VS 19.1B (YOY); EST 22.41B

DIVIS LABS: Q2 EBITDA 7.16B RUPEES VS 4.79B (YOY); EST 6.7B -- Q2 EBITDA MARGIN 30.62% VS 25.09% (YOY); EST 30%

DIVIS LABS: Q2 CONS NET PROFIT 5.1B RUPEES VS 3.48B (YOY); EST 4.89B

TARSONS PRODUCTS: CO SAYS COMMENCED COMMERCIAL PRODUCTION AT NEWLY SET UP PANCHLA PLANT

SMS PHARMA: Q2 EBITDA 315M RUPEES VS 278M (YOY) -- Q2 EBITDA MARGIN 15.99% VS 16.69% (YOY)

SMS PHARMA: Q2 CONS NET PROFIT 139M RUPEES VS 120.4M (YOY); 164M (QOQ) -- Q2 REVENUE 1.96B RUPEES VS 1.66B (YOY)

JUPITER LIFE LINE HOSPITALS: Q2 EBITDA 749.9M RUPEES VS 610M (YOY) -- Q2 EBITDA MARGIN 23.25% VS 23.19% (YOY)

JUPITER LIFE LINE HOSPITALS: Q2 REVENUE 3.2B RUPEES VS 2.6B (YOY)

JUPITER LIFE LINE HOSPITALS: Q2 CONS NET PROFIT 515M RUPEES VS 336M (YOY); 446M (QOQ)

METROPOLIS HEALTHCARE: Q2 EBITDA 899M RUPEES VS 748M (YOY) -- Q2 EBITDA MARGIN 25.70% VS 24.25% (YOY)

METROPOLIS HEALTHCARE: Q2 CONS NET PROFIT 465M RUPEES VS 354M (YOY); 379M (QOQ) -- Q2 REVENUE 3.5B RUPEES VS 3.08B (YOY)

FORTIS HEALTHCARE: CO HAS AN EXCEPTIONAL ITEM OF 597.7M RUPEES -- Q2 NET PROFIT BEFORE EXCEPTIONAL ITEM AND TAX 3.2B RUPEES VS 2.29B (YOY)

FORTIS HEALTHCARE: Q2 EBITDA 4.35B RUPEES VS 3.3B (YOY) -- Q2 EBITDA MARGIN 21.87% VS 18.65% (YOY)

FORTIS HEALTHCARE: Q2 REVENUE 19.9B RUPEES VS 17.7B (YOY)

FORTIS HEALTHCARE: Q2 CONS NET PROFIT 1.76B RUPEES VS 1.74B (YOY); 1.66B (QOQ)

VIMTA LAB: Q2 EBITDA 300M RUPEES VS 174M (YOY) -- Q2 EBITDA MARGIN 35.4% VS 26.5% (YOY)

VIMTA LAB: Q2 REVENUE 847M RUPEES VS 655M (YOY)

VIMTA LAB: Q2 CONS NET PROFIT 152M RUPEES VS 63M (YOY)

GRANULES INDIA: CO UNIT V FACILITY SECURES US FDA EIR WITH NO ACTION INDICATED STATUS

MAX HEALTHCARE: EXPECTS AN IMPROVEMENT IN MARGINS IN THE COMING QUARTERS DUE TO BETTER QUALITY PROGRAMS, HIGHER-END SURGICAL MIX, AND MORE ROBOTICS AND COMPLICATED SURGERIES - CONCALL UPDATE

MAX HEALTHCARE: CO EXPECTS A SIGNIFICANT RAMP-UP IN CAPACITY OVER THE NEXT 12-15 MONTHS, WITH A FOCUS ON THE MONTHS OF APRIL, MAY, AND JUNE - CONCALL UPDATE

APOLLO HOSPITALS: CO STILL EXPECTS HEALTHY YEAR-OVER-YEAR GROWTH IN THE THIRD QUARTER, DESPITE TRADITIONALLY SEEING A DECREASE IN VOLUME DURING THIS PERIOD -CONCALL UPDATE

LUPIN: US SALES OF USD 220M VS EST USD 232M

APOLLO HOSPITALS: CO EXPECTS THE EBITDA MARGIN TO COME DOWN BY AROUND 1% TO 1.2% DUE TO NEW HOSPITALS -- CO EXPECTS TO ACHIEVE BREAK-EVEN IN THE ONLINE SEGMENT IN FIVE TO SIX QUARTERS FROM NOW - CONCALL UPDATE

VIJAYA DIAGNOSTIC: CO EXPECTS TO MAINTAIN 40% EBITDA MARGINS FOR THE FULL FINANCIAL YEAR, DESPITE POTENTIAL QUARTERLY FLUCTUATIONS DUE TO NEW CENTER OPENINGS - CONCALL UPDATE

VIJAYA DIAGNOSTIC: CO IS CONFIDENT OF DELIVERING DOUBLE-DIGIT GROWTH OF 15% TO 16% THE CAPEX GUIDANCE FOR NEW CENTERS REMAINS AT APPROXIMATELY RUPEES 200 CR FOR FY25 AND FY26 - CONCALL UPDATE

LUPIN: Q2 EBITDA 13.4B RUPEES VS 9.2B (YOY); EST 12.2B -- Q2 EBITDA MARGIN 23.63% VS 18.21% (YOY); EST 22%

YATHARTH HOSPITAL & TRAUMA CARE SERVICES: CO APPROVES RAISING OF FUNDS UP TO 7 BLN RUPEES

LUPIN: Q2 REVENUE 56.7B RUPEES VS 50.4B (YOY); EST 55.65B

LUPIN: Q2 CONS NET PROFIT 8.5B RUPEES VS 4.9B (YOY); EST 7.47B - 8B (QOQ)

RPG LIFE SCIENCES: Q2 PBT 424M RUPEES VS 348M (YOY); 360M (QOQ)

RPG LIFE SCIENCES: Q2 EXCEPTIONAL ITEMS SEEN AT 273M IN Q2 FY25 RESULT

RPG LIFE SCIENCES: Q2 EBITDA 459M RUPEES VS 373M (YOY) -- Q2 EBITDA MARGIN 26.67% VS 24.28% (YOY)

RPG LIFE SCIENCES: Q2 SL NET PROFIT 42M RUPEES VS 259M (YOY); 268M (QOQ) -- Q2 REVENUE 1.7B RUPEES VS 1.54B (YOY)

SANOFI INDIA: Q2 EBITDA 1.2B RUPEES VS 1.1B (YOY) -- Q2 EBITDA MARGIN 22.84% VS 23.13% (YOY)

SANOFI INDIA: Q2 SL NET PROFIT FROM CONTINUING OPERATIONS 822M RUPEES VS 806M (YOY); 682M (QOQ) -- Q2 REVENUE 5.2B RUPEES VS 4.9B (YOY)

YATHARTH HOSPITAL & TRAUMA CARE SERVICES: Q2 EBITDA 546M RUPEES VS 456M (YOY) -- Q2 EBITDA MARGIN 25.09% VS 26.60% (YOY)

YATHARTH HOSPITAL & TRAUMA CARE SERVICES: Q2 REVENUE 2.18B RUPEES VS 1.7B (YOY)

YATHARTH HOSPITAL & TRAUMA CARE SERVICES: Q2 CONS NET PROFIT 309M RUPEES VS 276M (YOY); 303.8M (QOQ)

TARSONS PRODUCTS: Q2 EBITDA 235M RUPEES VS 254M (YOY) -- Q2 EBITDA MARGIN 29.34% VS 38.27% (YOY)

TARSONS PRODUCTS: Q2 SL NET PROFIT 129M RUPEES VS 128M (YOY); 65M (QOQ) -- Q2 REVENUE 801M RUPEES VS 663M (YOY)

VIJAYA DIAGNOSTIC CENTRE: Q2 EBITDA 760M RUPEES VS 573M (YOY) -- Q2 EBITDA MARGIN 41.54% VS 44.52% (YOY)

VIJAYA DIAGNOSTIC CENTRE: Q2 REVENUE 1.83B RUPEES VS 1.4B (YOY)

VIJAYA DIAGNOSTIC CENTRE: Q2 CONS NET PROFIT 419M RUPEES VS 333M (YOY)

CAPLIN POINT LAB: Q2 EBITDA 1.86B RUPEES VS 1.58B (YOY) -- Q2 EBITDA MARGIN 36.8% VS 36.7% (YOY)

CAPLIN POINT LAB: CO SAYS US MARKET H1 FY25 REVENUE AT RS 170 CRORES; AN INCREASE OF 40.8% (YOY)

CAPLIN POINT LAB: Q2 REVENUE 4.83B RUPEES VS 4.1B (YOY)

CAPLIN POINT LAB: Q2 CONS NET PROFIT 1.31B RUPEES VS 1.2B (YOY)

ALEMBIC PHARMA: Q2 EBITDA 2.4B RUPEES VS 2.1B (YOY) -- Q2 EBITDA MARGIN 14.56% VS 13.10% (YOY)

ALEMBIC PHARMA: Q2 REVENUE 16.48B RUPEES VS 15.9B (YOY)

ALEMBIC PHARMA: Q2 CONS NET PROFIT 1.5B RUPEES VS 1.3B (YOY)

LAURUS LABS LTD: Rs. 35.26 Crores NSE Block Trade; for ~ 714782 Shares, at Rs. 493.25

GRANULES INDIA: CO SAYS PHASE 2 OF THE FACILITY, WITH AN ADDITIONAL 7.5B DOSE CAPACITY, IS EXPECTED TO BE COMPLETED BY Q4 FY 25, WITH VALIDATION AND COMMERCIALIZATION ACTIVITIES SLATED TO BEGIN IN Q1 FY 26 - CONCALL UPDATE

GRANULES INDIA: CO SAYS THE MARGIN WILL NOT FALL SIGNIFICANTLY IN Q3 AND Q4, AND THE CO EXPECTS TO MAINTAIN A GOOD MARGIN RUN RATE -- CO IS PREPARING FOR NEW LAUNCHES FROM THE GPI SITE, WHICH WILL HELP LOWER THE IMPACT OF THE GAGILLAPUR SLOWDOWN IN Q2 - CONCALL UPDATE

GRANULES INDIA: CO EXPECTS TO SPEND UP TO USD 2M ON A SPECIFIC INITIATIVE (RASHMI) THIS YEAR -- CO EXPECTS A MODERATE MARGIN IN Q3, WITH REVENUE INCREASING BUT MARGIN FALLING A LITTLE BIT - CONCALL UPDATE

WOCKHARDT: CO LAUNCHES QIP WITH FLOOR PRICE OF RUPEES 1,162.25 PER SHARE -- CO SEEKS TO RAISE AS MUCH AS 1,000 CR RUPEES

GLOBAL HEALTH: MEDANTA TO OPERATE AND MANAGE A 750 BED SUPER SPECIALITY HOSPITAL IN NEW DELHI -- MEDANTA IS EXPECTED TO INCUR A PROJECT CAPEX OF 6 BLN RUPEES IN NEXT 3-4 YEARS

J.B. CHEMICALS & PHARMACEUTICALS: Q2 EBITDA 2.7B RUPEES VS 2.43B (YOY) -- Q2 EBITDA MARGIN 27.04% VS 27.62% (YOY)

J.B. CHEMICALS & PHARMACEUTICALS: Q2 CONS NET PROFIT 1.74B RUPEES VS 1.51B (YOY); 1.77B (QOQ) -- Q2 REVENUE 10B RUPEES VS 8.8B (YOY)

KRISHNA INSTITUTE OF MEDICAL SCIENCES: CO EXPANDS TO KERALA WITH A PLAN OF ESTABLISHING 3000 BEDS PROVIDING 10,000 POTENTIAL JOBS OVER THE NEXT 5 YEAR

J B CHEMICALS AND PHARMA: KKR IS SAID TO CONSIDER SELLING $750 MILLION STAKE IN JB PHARMA - BBG

FDC: CO HAS CONSIDERED AND APPROVED THE INTERIM DIVIDEND OF RUPEES 5 PER EQUITY SHARE

FDC: Q2 EBITDA 702M RUPEES VS 764M (YOY) -- Q2 EBITDA MARGIN 13.65% VS 15.71% (YOY)

FDC: Q2 REVENUE 5.1B RUPEES VS 4.9B (YOY)

FDC: Q2 CONS NET PROFIT 720M RUPEES VS 698M (YOY); 1.2B (QOQ)

APOLLO HOSPITALS ENTERPRISE: Q2 EBITDA 8.16B RUPEES VS 6.28B (YOY); EST 7.74B -- Q2 EBITDA MARGIN 14.59% VS 12.95% (YOY); EST 14%

APOLLO HOSPITALS ENTERPRISE: Q2 REVENUE 55.9B RUPEES VS 48.5B (YOY); EST 55.61B

APOLLO HOSPITALS ENTERPRISE: Q2 CONS NET PROFIT 3.8B RUPEES VS 2.33B (YOY); EST 3.6B - 3B (QOQ)

GLOBAL HEALTH: CO APPROVES O&M AGREEMENT FOR 750-BED HOSPITAL IN NEW DELHI -- CO WILL INVEST APPROXIMATELY RUPEES 600 CR IN NEXT 3-4 YEARS

GRANULES INDIA: Q2 EBITDA 2.03B RUPEES VS 2.13B (YOY) -- Q2 EBITDA MARGIN 21.04% VS 17.90% (YOY)

GRANULES INDIA: Q2 REVENUE 9.66B RUPEES VS 11.9B (YOY)

GRANULES INDIA: Q2 CONS NET PROFIT 972M RUPEES VS 1.02B (YOY)

NEULAND LABORATORIES: Q2 EBITDA 622M RUPEES VS 1.37B (YOY) -- Q2 EBITDA MARGIN 20.02% VS 32.91% (YOY)

NEULAND LABORATORIES: Q2 REVENUE 3.1B RUPEES VS 4.2B (YOY)

NEULAND LABORATORIES: Q2 CONS NET PROFIT 328M RUPEES VS 892M (YOY)

LAURUS LABS LTD: Rs. 23.10 Crores NSE Block Trade; for ~ 468317 Shares, at Rs. 493.30

LUPIN: MACQUARIE SAYS, US GENERIC PRICING EROSION HALTING THIS COULD DRIVE A RELIEF RALLY IN US GENERIC-HEAVY NAMES SUCH AS CO AND AUROBINDO PHARMA

AUROBINDO PHARMA: MACQUARIE SAYS, US GENERIC PRICING EROSION HALTING THIS COULD DRIVE A RELIEF RALLY IN US GENERIC-HEAVY NAMES SUCH AS CO AND LUPIN

GLENMARK : ICHNOS GLENMARK INNOVATION (IGI) ANNOUNCES FIRST PRESENTATION OF DATA FROM PHASE 1 STUDY OF THE TRISPECIFIC ISB 2001 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/RMM) AT UPCOMING ASH ANNUAL MEETING

MANKIND PHARMA: CO SAYS THE ACQUISITION IS FINANCED THROUGH A MIX OF DEBT, EQUITY, AND INTERNAL ACCRUALS, WITH A POTENTIAL EQUITY RAISE TO RETIRE A PORTION OF THE DEBT AND MAINTAIN A NET DEBT TO EBITDA RATIO BELOW 2X BY FY26 - CONCALL UPDATE

MANKIND PHARMA: CO EXPECTS 15% PLUS GROWTH IN THE SECOND HALF OF THE YEAR, AND 15% TO 20% GROWTH FOR THE FULL YEAR 2026 -- CO IS MAINTAINING ITS GUIDANCE OF 25% TO 26% MARGIN FOR CO - CONCALL UPDATE

DR REDDYS LAB: EUROPEAN COMMISSION GRANTED A MARKETING AUTHORIZATION FOR RITUXIMAB BIOSIMILAR, THE COMPANYS FIRST CHMP IN EUROPE - CONCALL UPDATE

DR REDDYS LAB: CO IS WAITING FOR USFDA APPROVALS FOR A COUPLE OF PRODUCTS, HOPING TO SEE APPROVALS IN Q3, BUT NO GUARANTEE -- CO SUBMITTED A RESPONSE TO THE USFDA AND IS WAITING FOR APPROVAL, LIKELY IN THE FIRST PART OF FY 26 - CONCALL UPDATE

DR REDDYS LAB: GUIDANCE - NORMALIZED EFFECTIVE TAX RATE (ETR) IS EXPECTED TO BE AROUND 25% FOR THE FISCAL - CONCALL UPDATE

DR REDDYS LAB: GUIDANCE - SG&A SPEND IS EXPECTED TO BE IN THE RANGE OF 27.5% TO 28% FOR THE FULL FISCAL -- R&D SPEND IS EXPECTED TO BE IN THE RANGE OF 8.5% TO 9% FOR THE FULL FISCAL - CONCALL UPDATE

NARAYANA HRUDAYALAYA: CO IS INVESTING IN THE LATEST MODULARITY FOR TREATING PATIENTS, INCLUDING ROBOTIC SURGERY AND IMMUNE THERAPY FOR CANCER TREATMENT -- CO IS FOCUSED ON PRODUCT BUILDING, WITH AN ORGANIC APPROACH, WHICH MAY IMPACT REVENUE IN THE NEXT YEAR OR TWO - CONCALL UPDATE

NARAYANA HRUDAYALAYA: CO EXPECTS THE INTERNATIONAL BUSINESS TO GO TO ZERO OVER THE NEXT 10 YEARS -- CO IS CONFIDENT THAT MEASURES TO CONTROL STARTUP COSTS HAVE BEEN SUCCESSFUL, AND THEY EXPECT TO RETURN TO PRE-COMMISSIONING MARGINS IN FOUR TO FIVE QUARTERS - CONCALL UPDATE

NARAYANA HRUDAYALAYA: CO REVISED ITS ESTIMATE FOR MARGIN DILUTION FROM 6-8 WEEKS TO 4-5 QUARTERS -- CO EXPECTS MARGIN DILUTION TO LAST FOR 4-5 QUARTERS AFTER THE HOSPITAL IS FULLY COMMISSIONED - CONCALL UPDATE

MAX HEALTHCARE INSTITUTE: CO SAYS COMMENCED OPERATIONS AT MAX SUPER SPECIALTY HOSPITAL (MSSH), DWARKA -- CO SAYS ACQUIRED CONTROLLING STAKE IN JAYPEE HEALTHCARE LTD

MAX HEALTHCARE INSTITUTE: Q2 EBITDA 4.51B RUPEES VS 3.87B (YOY) -- Q2 EBITDA MARGIN 26.39% VS 28.42% (YOY)

MAX HEALTHCARE INSTITUTE: Q2 REVENUE 17.07B RUPEES VS 13.6B (YOY)

MAX HEALTHCARE INSTITUTE: Q2 CONS NET PROFIT 2.82B RUPEES VS 2.77B (YOY); 2.36B (QOQ)

MANKIND PHARMA: CO SAYS APPROVED PLEDGE OF EQUITY SHARES OF UNIT BHARAT SERUMS AND VACCINES

MANKIND PHARMA: Q2 EBITDA 8.5B RUPEES VS 6.83B (YOY) -- Q2 EBITDA MARGIN 27.63% VS 25.21% (YOY)

DR. REDDYS LABORATORIES: Q2 EBITDA 20.8B RUPEES VS 19.85B (YOY); EST 21.6B -- Q2 EBITDA MARGIN 25.83% VS 29% (YOY); EST 28% (CORRECTION)

MANKIND PHARMA: Q2 REVENUE 30.8B RUPEES VS 27.1B (YOY)

MANKIND PHARMA: Q2 CONS NET PROFIT 6.5B RUPEES VS 5B (YOY); 5.4B (QOQ)

DR REDDYS: CO APPROVES FUND INFUSION VIA INVESTMENT IN SHARES OF UNIT FOR UPTO 6 BLN RUPEES

DR. REDDYS LABORATORIES: Q2 EBITDA 20.8B RUPEES VS 20.1B (YOY); EST 216B -- Q2 EBITDA MARGIN 25.83% VS 29.09% (YOY); EST 28%

DR. REDDYS LABORATORIES: Q2 REVENUE 80.3B RUPEES VS 69B (YOY); EST 77.21B

DR. REDDYS LABORATORIES: Q2 CONS NET PROFIT 12.6B RUPEES VS 14.8B (YOY); EST 14.7B - 13.9B (QOQ)

GLAND PHARMA: CO EXPECTS 1X TO 2X ASSET TURN AT CENEXI IN THE MID-TERM, DRIVEN BY COMMERCIALIZATION OF NEW CAPACITY, INCLUDING THE PFS LINE, NEW AMPOULE LINE, AND OTHER LINES - CONCALL UPDATE

GLAND PHARMA: CO EXPECTS TO RETURN TO ITS OLD 10% EBITDA LEVEL THE YEAR AFTER NEXT, ONCE ALL CAPACITY IS ON STREAM AND PIPELINE PROJECTS ARE COMMERCIALLY ONLINE. CENEXIS REVENUE IS EXPECTED TO REACH EUR 200M NEXT YEAR, REPRESENTING 0.8X GROWTH - CONCALL UPDATE

GLAND PHARMA: CO IS TARGETING TO ACHIEVE GROWTH AFTER THE NEW LINE IS UP AND RUNNING FROM JANUARY. CO EXPECTS TO BE EBITDA NEUTRAL OR LOW SINGLE-DIGIT NEXT YEAR AFTER THE NEW LINE AND ADDITIONAL CAPEX ARE COMPLETED - CONCALL UPDATE

GLAND PHARMA: CO SAYS DESPITE THESE NEAR-TERM HEADWINDS, WE CONTINUE TO STRIVE TO ACHIEVE OUR SHORT-TERM OUTLOOK: A POSITIVE EBITDA FOR Q4 OF FY25 -- WE MAINTAIN OUR GOAL OF A POSITIVE EBITDA FOR THE NEXT FISCAL YEAR, DRIVEN BY AN INCREASE IN REVENUE ABOVE THE €200 MILLION THRESHOLD - INVESTOR PRESENTATION

PROCTER & GAMBLE HEALTH: Q2 EBITDA 1.14B RUPEES VS 887M (YOY) -- Q2 EBITDA MARGIN 36.39% VS 29.08% (YOY)

PROCTER & GAMBLE HEALTH: Q2 REVENUE 3.1B RUPEES VS 3.05B (YOY)

PROCTER & GAMBLE HEALTH: Q2 SL NET PROFIT 823M RUPEES VS 656M (YOY); 168M (QOQ)

GLAND PHARMA: Q2 EBITDA 3B RUPEES VS 3.2B (YOY) -- Q2 EBITDA MARGIN 21.13% VS 23.60% (YOY)

GLAND PHARMA: Q2 REVENUE 14.06B RUPEES VS 13.7B (YOY)

GLAND PHARMA: Q2 CONS NET PROFIT 1.6B RUPEES VS 1.94B (YOY); 1.44B (QOQ)

SUN PHARMA ADVANCED RESEARCH: Q2 REVENUE 128M RUPEES VS 211M (YOY)

SUN PHARMA ADVANCED RESEARCH: Q2 REVENUE 128M RUPEES VS 211M (YOY)

SUN PHARMA ADVANCED RESEARCH: Q2 CONS NET LOSS 1.07B RUPEES VS LOSS 860M (YOY)

TORRENT PHARMACEUTICALS LTD: RS. 63.88 CRORES NSE BLOCK TRADE; FOR ~ 201553 SHARES, AT RS. 3169.15

DR REDDYS: CO RECALLS OVER 3.3 LAKH BOTTLES OF GENERIC MEDICATION IN U.S.: USFDA - ET

APOLLO HOSPITALS: CO SAYS TOTAL ESTIMATED PROJECT COST FOR THE 11 PROJECTS IS 61B RUPEES

APOLLO HOSPITALS: CO PLANS TO ADD OVER 3512 CAPACITY BEDS OVER NEXT 4 YRS IN 11 LOCATIONS IN INDIA

APOLLO HOSPITALS: APOLLO MEDICS PROPOSES TO EXPAND HOSPITAL IN LUCKNOW TO 500 BEDS FROM 300 BEDS

APOLLO HOSPITALS: CO UNIT PROPOSES TO ESTABLISH A 500 BED HOSPITAL IN WORLI MUMBAI

INDRAPRASTHA MEDICAL CORP: CO ISSUES DISCLOSURE REGARDING MEDIA ALLEGATIONS CONCERNING AN ASSOCIATE DOCTOR -- CO SAYS ALLEGED IRREGULARITIES ON KIDNEY TRANSPLANT PRACTICES NOT AT OUR HOSPITAL

NARAYANA HRUDAYALAYA: Q2 EBITDA 3.08B RUPEES VS 3.08B (YOY) -- Q2 EBITDA MARGIN 22.03% VS 23.61% (YOY)

NARAYANA HRUDAYALAYA: Q2 REVENUE 14B RUPEES VS 13.05B (YOY)

NARAYANA HRUDAYALAYA: Q2 CONS NET PROFIT 1.99B RUPEES VS 2.27B (YOY); 2.01B (QOQ)

SHILPA MEDICARE: CONCLUSION OF USFDA INSPECTION WITH 4 OBSERVATIONS -- ALL OBSERVATIONS ARE PROCEDURAL IN NATURE

CIPLA LTD: CO UPDATES REGARDING ROUTINE (CGMP) INSPECTION AT CO UNIT IN GOA BETWEEN 10TH – 21ST JUNE, 2024, USFDA HAS CLASSIFIED INSPECTION AS VOLUNTARY ACTION INDICATED

BIOCON: COS BIOSIMILARS SEGMENT REPORTED 59% TOTAL REVENUE, WHEREAS RESEARCH SERVICES CONTRIBUTED 24% AND GENERICS 17%

SASTASUNDAR VENTURES: CO PROJECTING A PROVISIONAL REVENUE OF RS.238 CRORE IN Q2 FY25 - INVESTOR PRESENTATION

SASTASUNDAR VENTURES: CO ESTIMATE AN INVESTMENT OF RS.115 CRORES IN THE NEXT THREE YEARS IN TECHNOLOGY AND BRAND BUILDING AND BY THIS INVESTMENT THE PLATFORM IS ESTIMATED TO BE PROFITABLE - INVESTOR PRESENTATION

BIOCON: CO SAYS MAINTAIN OUTLOOK FOR TRANSITION TO ACCELERATING GROWTH IN H2 (CORRECT)

BIOCON: CO MAINTAIN OUR OUTLOOK FOR TRANSITION TO ACCELERATING GROWTH IN H2

YATHARTH HOSPITAL: CO TO ACQUIRE 60% STAKE IN MGS INFOTECH RESEARCH AND SOLUTIONS -- ACQUISITION AT ENTERPRISE VALUE OF1.52B RUPEES -- ACQUISITION OF 60% STAKE IN MGS INFOTECH RESEARCH FOR 912M RUPEES

BIOCON: Q2 EBITDA 6.85B RUPEES VS 7.4B (YOY); EST 7.4B -- Q2 EBITDA MARGIN 19.09% VS 21% (YOY); EST 20%

BIOCON: Q2 REVENUE 35.9B RUPEES VS 34.6B (YOY); EST 36.6B

BIOCON: Q2 CONS NET PROFIT 271M RUPEES VS 1.7B (YOY); EST 547M; 8.6B (QOQ)

MAX HEALTHCARE INSTITUTE: CO TO CONSIDER Q2 RESULTS ON NOV 5

BIOCON: BIOCON BIOLOGICS’ DRUG SUBSTANCE FACILITY IN BENGALURU CLASSIFIED AS VOLUNTARY ACTION INDICATED (VAI)

INDRAPRASTHA MEDICAL CORP: Q2 EBITDA 636M RUPEES VS 504M (YOY) -- Q2 EBITDA MARGIN 18.19% VS 15.89% (YOY)

INDRAPRASTHA MEDICAL CORP: Q2 REVENUE 3.5B RUPEES VS 3.17B (YOY)

INDRAPRASTHA MEDICAL CORP: Q2 SL NET PROFIT 424M RUPEES VS 328M (YOY); 448M (QOQ)

LAURUS LABS LTD: RS. 152.52 CRORES NSE BLOCK TRADE; FOR ~ 3146284 SHARES, AT RS. 484.75

SHALBY: Q2 EBITDA 326M RUPEES VS 527M (YOY) -- Q2 EBITDA MARGIN 12.19% VS 22.14% (YOY)

SHALBY: Q2 EBITDA 326M RUPEES VS 527M (YOY) -- Q2 EBITDA MARGIN 12.19% VS 22.14% (YOY)

SHALBY: Q2 REVENUE 2.7B RUPEES VS 2.4B (YOY)

SHALBY: Q2 CONS NET PROFIT 24M RUPEES VS 276M (YOY)

INDOCO REMEDIES: CO RECEIVES FINAL ANDA APPROVAL FROM USFDA FOR VARENICLINE TABLETS

TORRENT PHARMA: RS 3100.16CR BSE BLOCK TRADE; FOR ~9974777 SHARES, AT RS 3108

TORRENT PHARMA: BLOCK DEAL ALERT - PROMOTER TO SELL UPTO 2.9% STAKE VIA BLOCK DEAL -- BASE OFFER SIZE IS OF 83 LAKH SHARES OR 2.4% STAKE WORTH 2500 CR -- GREENSHOE OPTION FOR 16.5 LAKH SHARES -- OFFER FLOOR PRICE IS RS 3022.7 – 6% DISCOUNT TO CMP -- DEAL SIZE OF NEARLY RS 3000 CR - CNBC AWAAZ

YATHARTH HOSPITAL: CO DECLARED AS SUCCESSFUL BIDDER FOR SUPER SPECIALTY HOSPITAL IN DELHI -- HOSPITAL HAS AN EXPANDABLE CAPACITY OF 300 PLUS BEDS AND CATERS TO A LARGE CATCHMENT OF RESIDENTIAL AND INSTITUTIONAL CLIENT BASE

FORTIS HEALTHCARE: INDIA CCI APPROVES THE ACQUISITION OF ADDITIONAL 31.52% SHARE CAPITAL OF AGILUS DIAGNOSTICS LIMITED BY FORTIS HEALTHCARE LTD

GLAXOSMITHKLINE PHARMA: CO HAS AN EXCEPTIONAL ITEM OF 47M RUPEES -- Q2 PBT 3.4B VS 2.9B RUPEES (YOY)

GLAXOSMITHKLINE PHARMA: CO DECLARED A SPECIAL INTERIM DIVIDEND OF RUPEES 12 PER EQUITY SHARE

GLAXOSMITHKLINE PHARMA: Q2 EBITDA 3.2B RUPEES VS 2.9B (YOY) -- Q2 EBITDA MARGIN 31.83% VS 30.25% (YOY)

GLAXOSMITHKLINE PHARMA: Q2 REVENUE 10B RUPEES VS 9.6B (YOY)

GLAXOSMITHKLINE PHARMA: Q2 CONS NET PROFIT 2.5B RUPEES VS 2.2B (YOY); 1.8B (QOQ)

CIPLA: Q2 EBITDA 18.9B RUPEES VS 17.34B (YOY); EST 18.22B -- Q2 EBITDA MARGIN 26.7% VS 25.97% (YOY); EST 26%

CIPLA: Q2 REVENUE 70.5B RUPEES VS 67B (YOY); EST 70.42B

CIPLA: Q2 CONS NET PROFIT 13B RUPEES VS 11.3B (YOY); EST 12.5B

BLUE JET HEALTHCARE: Q2 EBITDA 694M RUPEES VS 626M (YOY) -- Q2 EBITDA MARGIN 33.33% VS 34.53% (YOY)

BLUE JET HEALTHCARE: Q2 REVENUE 2.1B RUPEES VS 1.8B (YOY)

BLUE JET HEALTHCARE: Q2 SL NET PROFIT 583M RUPEES VS 478M (YOY)

BLUE JET HEALTHCARE: Q2 SL NET PROFIT 583M RUPEES VS 478M (YOY)

SUVEN LIFE SCIENCES: Q2 SL NET LOSS 110M RUPEES VS PROFIT 27M (YOY) -- Q2 REVENUE 26M RUPEES VS 31M (YOY)

AMI ORGANICS: CO MD SAYS WE ARE RAISING OUR REVENUE GROWTH GUIDANCE FOR FY25 FROM 25% TO 30%

AMI ORGANICS: Q2 EBITDA 481M RUPEES VS 186.1M (YOY) -- Q2 EBITDA MARGIN 19.76% VS 11.38% (YOY)

AMI ORGANICS: Q2 REVENUE 2.44B RUPEES VS 1.6B (YOY)

AMI ORGANICS: Q2 SL NET PROFIT 377M RUPEES VS LOSS 209.5M (YOY)

CIPLA: UBS SAYS SUN PHARMA LAUNCH OF LANREOTIDE CAN IMPACT CIPLA -- UBS CIPLA LANREOTIDE IS VERY BIG CONTRIBUTOR AT $120-130MN , SUN TO GAIN SIGNIFICANT MARKET SHARE

AJANTA PHARMA: CO EBITDA MARGIN IS EXPECTED TO BE AROUND 28% PLUS MINUS 0.5% OR 1% FOR THE WHOLE YEAR -- US BUSINESS IS EXPECTED TO GROW AT A MID-SINGLE-DIGIT RATE FOR FY 2025 -- BRANDED GENERIC BUSINESS IS EXPECTED TO GROW AT A MID-TEENS RATE FOR FY 2025 - CONCALL UPDATE

AJANTA PHARMA: COM EXPECTS GROSS MARGIN TO REMAIN IN A SIMILAR RANGE WITH QUARTERLY MOVEMENT OF 50 BASIS POINTS TO 100 BASIS POINTS DUE TO CHANGE IN PRODUCT MIX - CONCALL UPDATE

SUN PHARMA: CO EXPECTS THE PRICING PRESSURE FROM JAPAN TO CONTINUE AFFECTING PERFORMANCE IN THE NEXT FEW QUARTERS - CONCALL UPDATE

SUN PHARMA: CO ENTERED INTO A GLOBAL LICENSING AGREEMENT FOR COMMERCIALIZING FIBROMUN, AN ANTI-CANCER IMMUNOTHERAPY, WHICH IS BEING INVESTIGATED IN REGISTRATION TRIALS FOR THE TREATMENT OF SOFT TISSUE SARCOMA AND SUBSEQUENTLY FOR GLIOBLASTOMA - CONCALL UPDATE

SUN PHARMA: CO EXPECTS ITS FY25 R&D SPEND TO BE IN THE RANGE OF 7% TO 8% OF SALES -- THE NEW GUIDANCE IS BASED ON THE COS REASSESSMENT OF THE MONEY IT WILL NEED TO SPEND DURING THE SECOND HALF OF THE YEAR - CONCALL UPDATE

INDEGENE: Q2 EBITDA 1.26B RUPEES VS 1.2B (YOY) -- Q2 EBITDA MARGIN 18.36% VS 19.05% (YOY)

INDEGENE: Q2 CONS NET PROFIT 917M RUPEES VS 750M (YOY); 877M (QOQ) -- Q2 REVENUE 6.86B RUPEES VS 6.36B (YOY)

PFIZER: Q2 EBITDA 1.9B RUPEES VS 1.8B (YOY) -- Q2 EBITDA MARGIN 32.09% VS 31.61% (YOY)

PFIZER: Q2 SL NET PROFIT 1.6B RUPEES VS 1.48B (YOY); 1.5B (QOQ) -- Q2 REVENUE 5.9B RUPEES VS 5.75B (YOY)

SASTASUNDAR VENTURES: CO SAYS SALE OF ENTIRE STAKE HELD IN FLIPKART HEALTH BY UNIT -- TOTAL CONSIDERATION FOR DEAL AT 971.7M RUPEES

DR. REDDYS LABORATORIES: CO LAUNCHES ELOBIXIBAT (BIXIBAT®) A FIRST-IN-CLASS DRUG TO TREAT CHRONIC CONSTIPATION IN INDIA

AJANTA PHARMA: CO HAS APPROVED 1ST INTERIM DIVIDEND OF RUPEES 28 PER SHARE

AJANTA PHARMA: Q2 EBITDA 3.1B RUPEES VS 2.9B (YOY) -- Q2 EBITDA MARGIN 26.22% VS 28.26% (YOY)

AJANTA PHARMA: Q2 REVENUE 11.9B RUPEES VS 10.28B (YOY)

AJANTA PHARMA: Q2 CONS NET PROFIT 2.16B RUPEES VS 1.9B (YOY); 2.45B (QOQ)

SUN PHARMA INDUSTRIES: Q2 REVENUE 133B RUPEES VS 122B (YOY); EST 133B

SUN PHARMA INDUSTRIES: US FORMULATION SALES AT US$ 517 MILLION, UP 20.3% VS EST USD 480M

SUN PHARMA INDUSTRIES: US FORMULATION SALES AT USD 517 MILLION, UP 20.3%

SUN PHARMA INDUSTRIES: Q2 EBITDA 39.4B RUPEES VS 31.8B (YOY); EST 39.6B -- Q2 EBITDA MARGIN 29.6% VS 26.08% (YOY); EST 30%

SUN PHARMA INDUSTRIES: Q2 CONS NET PROFIT 30B RUPEES VS 23.8B (YOY); EST 28.95B

POLY MEDICURE: Q2 EBITDA 1.15B RUPEES VS 842M (YOY) -- Q2 EBITDA MARGIN 27.41% VS 24.97% (YOY)

POLY MEDICURE: Q2 REVENUE 4.2B RUPEES VS 3.37B (YOY)

POLY MEDICURE: Q2 CONS NET PROFIT 874M RUPEES VS 622M (YOY)

SUPRIYA LIFESCIENCE: Q2 EBITDA 647M RUPEES VS 318M (YOY) -- Q2 EBITDA MARGIN 38.95% VS 22.70% (YOY)

SUPRIYA LIFESCIENCE: Q2 REVENUE 1.66B RUPEES VS 1.4B (YOY)

SUPRIYA LIFESCIENCE: Q2 SL NET PROFIT 462M RUPEES VS 239M (YOY)

HEALTHCARE GLOBAL: KKR IN TALKS TO ACQUIRE CANCER HOSPITAL CHAIN HCG FROM CVC CAPITAL

HESTER BIOSCIENCES: Q2 EBITDA 192M RUPEES VS 132M (YOY) -- Q2 EBITDA MARGIN 22.94% VS 18.72% (YOY)

HESTER BIOSCIENCES: Q2 CONS NET PROFIT 84M RUPEES VS 41M (YOY) -- Q2 REVENUE 837M RUPEES VS 705M (YOY)

GLENMARK LIFESCIENCES: DOUBLE UPGRADE BY KOTAK ON GLENMARK LIFE SCIENCES-- UPGRADE FROM REDUCE TO BUY-- 2QFY25 DENTED BY TEMPORARY CLOSURE IN ANKLESHWAR CURATED API PORTFOLIO &WITH RICH PIPELINE & CDMO CLIENT WINS TO DRIVE GROWTH

KRSNAA DIAGNOSTICS: Q2 EBITDA 494M RUPEES VS 318M (YOY) -- Q2 EBITDA MARGIN 26.52% VS 20.46% (YOY)

KRSNAA DIAGNOSTICS: Q2 CONS NET PROFIT 196M RUPEES VS 105M (YOY); 179M (QOQ) -- Q2 REVENUE 1.86B RUPEES VS 1.55B (YOY)

SUN PHARMA: CO PRESENTS LEQSELVITM DATA HIGHLIGHTING CLINICAL EFFICACY & DURABILITY -- DATA AT 68 WEEKS OF TREATMENT WITH LEQSELVI SHOWED MEANINGFUL IMPROVEMENT IN SCALP HAIR REGROWTH

THEMIS MEDICARE: Q2 EBITDA 170M RUPEES VS 32.6M (YOY) -- Q2 EBITDA MARGIN 17.09% VS 4.44% (YOY)

THEMIS MEDICARE: Q2 REVENUE 996M RUPEES VS 735M (YOY)

THEMIS MEDICARE: Q2 SL NET PROFIT 99M RUPEES VS 71M (YOY); 187M (QOQ)

SUN PHARMA: STUDIES SHOW SUN PHARMAS WINLEVI® (CLASCOTERONE) CREAM 1% REDUCES SEBUM LEVELS AND IS SUITABLE FOR COMBINATION WITH OTHER COMMONLY USED TOPICAL ACNE MEDICATIONS - RTRS

TORRENT PHARMACEUTICALS: Q2 EBITDA 9.4B RUPEES VS 8.25B (YOY) -- Q2 EBITDA MARGIN 32.50% VS 31.02% (YOY)

STRIDES PHARMA SCIENCE: CO UNIT SPG ACQUIRES REMAINING STAKE IN STRIDES SWITZERLAND FOR CHF 1.01M

TORRENT PHARMACEUTICALS: Q2 CONS NET PROFIT 4.53B RUPEES VS 3.86B (YOY); 4.57B (QOQ) -- Q2 REVENUE 28.9B RUPEES VS 26.60B (YOY)

AUROBINDO PHARMA: CO SAYS COMPLETION OF ACQUISITION OF BALANCE 49% OF EQUITY SHARES OF GLS PHARMA FOR A PURCHASE CONSIDERATION OF INR 22.5 CRORES -- GLS HAS BECOME A WHOLLY OWNED SUBSIDIARY OF THE CO

ERIS LIFESCIENCES: CO SAYS ON TRACK TO DELIVER FY 25 GUIDANCE - DBF REVENUE AT RUPEES 2600 CR; DBF EBITDA MARGIN 36%

ERIS LIFESCIENCES: BHOPAL PLANT - COMMENCING PRODUCTION OF RHI VIALS FROM NOV 24, GROSS MARGIN BENEFITS TO ACCRUE STARTING Q4-FY25/Q1-FY26

ERIS LIFESCIENCES: DEAL FOR PRIMARY EQUITY INVESTMENT OF 540M RUPEES

ERIS LIFESCIENCES: Q2 EBITDA 2.64B RUPEES VS 1.8B (YOY) -- Q2 EBITDA MARGIN 35.7% VS 35.85% (YOY)

ERIS LIFESCIENCES: Q2 REVENUE 7.4B RUPEES VS 5B (YOY)

ERIS LIFESCIENCES: Q2 CONS NET PROFIT 910M RUPEES VS 1.23B (YOY)

JUBILANT PHARMOVA: Q2 EBITDA 2.89B RUPEES VS 2.4B (YOY) -- Q2 EBITDA MARGIN 16.6% VS 14.39% (YOY)

JUBILANT PHARMOVA: Q2 REVENUE 17.5B RUPEES VS 16.8B (YOY)

JUBILANT PHARMOVA: Q2 CONS NET PROFIT 1B RUPEES VS 625M (YOY)

STRIDES PHARMA: CO IS PREPARING FOR THE LAUNCH OF SEMA, WITH CUSTOMERS BOOKING CAPACITIES STARTING AS EARLY AS AUGUST NEXT YEAR -- CO HAS A THREE TO FIVE-YEAR PRODUCT COMMERCIALIZATION TIMEFRAME, WITH A SIGNIFICANT R&D INCOME EXPECTED DURING THIS PERIOD - CONCALL UPDATE

STRIDES PHARMA: CO IS FOCUSED ON MARGIN EXPANSION, WITH A GOAL OF ACHIEVING USD 350M TO USD 400M IN EBITDA IN THREE TO FOUR YEARS - CONCALL UPDATE

STRIDES PHARMA: CO EXPECTS TO REACH AN ANNUALIZED EXIT RUN RATE OF USD 80M IN THE BUSINESS -- CO IS GUIDING USD 300M, USD 400M REVENUES OVER THE NEXT THREE TO FOUR YEARS - CONCALL UPDATE

ASTER DM HEALTHCARE: CO PLANS TO ADD NEARLY 1,900 BEDS OVER THE NEXT THREE YEARS, WHICH WILL REQUIRE A TOTAL CAPITAL EXPENDITURE OF AROUND RS 1,450 CR - CONCALL UPDATE

ASTER DM HEALTHCARE: CO AIMS TO INCREASE THE NON-ASTER BUSINESS COMPONENT OF ITS LAB BUSINESS FROM 28% TO NEAR 50% IN THE NEXT TWO TO THREE YEARS, WHICH COULD LEAD TO A MARGIN ABOVE 20% - CONCALL UPDATE

SYNGENE INTERNATIONAL: CO EXPECTS TO EXECUTE USD 60M CAPEX BY THE END OF THE YEAR, FOCUSING ON EXECUTING IN LINE WITH ITS STRATEGY, DELIVERING ON PILOTS, AND PROCESS DEVELOPMENT PROJECTS - CONCALL UPDATE

SYNGENE INTERNATIONAL: CO EXPECTS THE EFFECTIVE TAX RATE FOR THE FULL YEAR TO BE AROUND 22% TO 23% -- CO EXPECTS LONG-TERM RAW MATERIAL COST TO BE AROUND 28% OF REVENUE - CONCALL UPDATE

AARTI DRUGS: CO SAYS FULL RAMP-UP OF EXISTING CAPACITY AND NEW CAPACITY POST RS. 600 CRORES CAPEX REVENUE POTENTIAL: RS. 4,200 – 4,500 CRORES WITH HIGHER MARGIN PROFILE IN NEXT 5-6 YEARS -INVESTOR PRESENTATION

LAURUS LABS: CO EXPECTS HEALTHY GROWTH IN FY25 -- CO IS "WELL ON TRACK TO DELIVER FULL-YEAR GROWTH OUTLOOK" DRIVEN BY FACILITY RAMP-UP AND SCHEDULED CDMO PROJECT DELIVERIES IN THE SECOND HALF OF THE FINANCIAL YEAR - CONCALL UPDATE

AARTI DRUGS: CO CFO SAYS PRODUCTION OF SALICYLIC ACID HAS COMMENCED AND CURRENTLY WE ARE PRODUCING 100 TONNES PER MONTH -- CO EXPECT TO RAMP UP THE PRODUCTION TO 300+ TONNES BY END OF OCT 24 -- SEQUENTIAL RAMP UP OF CAPACITY TO 1,800 TONNES THROUGHOUT FY25 & FY26

AARTI DRUGS: Q2 EBITDA 670.5M RUPEES VS 765M (YOY) -- Q2 EBITDA MARGIN 11.21% VS 11.92% (YOY)

AARTI DRUGS: Q2 REVENUE 5.98B RUPEES VS 6.4B (YOY)

AARTI DRUGS: Q2 CONS NET PROFIT 350.1M RUPEES VS 369M (YOY); 332.4M (QOQ)

BLISS GVS PHARMA: Q2 EBITDA 415M RUPEES VS 543M (YOY) -- Q2 EBITDA MARGIN 19.06% VS 25.66% (YOY)

BLISS GVS PHARMA: Q2 REVENUE 2.18B RUPEES VS 2.1B (YOY)

BLISS GVS PHARMA: Q2 CONS NET PROFIT 243M RUPEES VS 423M (YOY); 207M (QOQ)

GLENMARK LIFE SCIENCES: Q2 EBITDA 1.3B RUPEES VS 1.7B (YOY) -- Q2 EBITDA MARGIN 26.51% VS 28.06% (YOY)

GLENMARK LIFE SCIENCES: Q2 REVENUE 5.1B RUPEES VS 6B (YOY)

GLENMARK LIFE SCIENCES: Q2 SL NET PROFIT 953M RUPEES VS 1.2B (YOY); 1.1B (QOQ)

LAURUS LABS: Q2 EBITDA 1.79B RUPEES VS 1.87B (YOY) -- Q2 EBITDA MARGIN 14.62% VS 15.34% (YOY)

LAURUS LABS: Q2 REVENUE 12.24B RUPEES VS 12.2B (YOY)

LAURUS LABS: Q2 CONS NET PROFIT 198M RUPEES VS 370M (YOY)

STRIDES PHARMA SCIENCE: US REVENUES AT A HISTORIC HIGH OF $75M IN Q2FY25, GREW 26.2% (YOY)

STRIDES PHARMA SCIENCE: Q2 EBITDA 2.35B RUPEES VS 1.53B (YOY) -- Q2 EBITDA MARGIN 19.62% VS 15.33% (YOY)

STRIDES PHARMA SCIENCE: Q2 REVENUE 12B RUPEES VS 10B (YOY)

STRIDES PHARMA SCIENCE: Q2 CONS NET PROFIT 932M RUPEES VS LOSS 1.3B (YOY)

INDOCO REMEDIES: Q2 EBITDA 402.5M RUPEES VS 714M (YOY) -- Q2 EBITDA MARGIN 9.35% VS 14.82% (YOY)

INDOCO REMEDIES: Q2 REVENUE 4.3B RUPEES VS 4.8B (YOY)

INDOCO REMEDIES: Q2 CONS NET LOSS 96M RUPEES VS 351M (YOY)

MANKIND PHARMA: CO COMPLETES BHARAT SERUM ACQUISITION FOR RUPEES 137.7B

PIRAMAL PHARMA: CO CHAIRPERSON SAYS HAVE ANNOUNCED A US$80MN EXPANSION PLAN AT OUR LEXINGTON FACILITY WHICH IS EXPECTED TO GET COMPLETE BY END FY27 -- REMAIN COMMITTED TO ACHIEVING OUR FINANCIAL GOALS OF US$2 BN REVENUE WITH 25% EBITDA MARGIN AND 1X NET DEBT / EBITDA BY FY30

ASTER DM HEALTHCARE: Q2 EBITDA 2.17B RUPEES VS 1.42B (YOY) -- Q2 EBITDA MARGIN 19.99% VS 15.29% (YOY)

ASTER DM HEALTHCARE: Q2 REVENUE 10.86B RUPEES VS 9.29B (YOY)

ASTER DM HEALTHCARE: Q2 CONS NET PROFIT 968.4M RUPEES VS LOSS 308M (YOY); PROFIT 51.45B (QOQ)

PIRAMAL PHARMA: Q2 EBITDA 3.4B RUPEES VS 2.66B (YOY) -- Q2 EBITDA MARGIN 15.25% VS 13.90% (YOY)

PIRAMAL PHARMA: Q2 CONS NET PROFIT 226M RUPEES VS 50.2M (YOY); LOSS 886M (QOQ) -- Q2 REVENUE 22.4B RUPEES VS 19.11B (YOY)

THYROCARE TECHNOLOGIES: Q2 EBITDA 483M RUPEES VS 375M (YOY) -- Q2 EBITDA MARGIN 27.23% VS 25.35% (YOY)

THYROCARE TECHNOLOGIES: Q2 REVENUE 1.8B RUPEES VS 1.48B (YOY)

THYROCARE TECHNOLOGIES: Q2 CONS NET PROFIT 267M RUPEES VS 203M (YOY); 242M (QOQ)

DR LAL PATHLABS: CO APPROVED SECOND INTERIM DIVIDEND OF 6 RUPEES PER EQUITY SHARE

DR. LAL PATH LABS: Q2 EBITDA 2.02B RUPEES VS 1.78M (YOY); EST 1.96B -- Q2 EBITDA MARGIN 30.7% VS 29.6% (YOY); EST 29.2%

DR. LAL PATH LABS: Q2 REVENUE 6.6B RUPEES VS 6B (YOY); EST 6.7B

DR. LAL PATH LABS: Q2 CONS NET PROFIT 1.3B RUPEES VS 1.1B (YOY); EST 1.25B; 1.07B (QOQ)

SYNGENE INTERNATIONAL: Q2 REVENUE 8.9B RUPEES VS 9.1B (YOY)

SYNGENE INTERNATIONAL: Q2 EBITDA 2.45B RUPEES VS 2.54B (YOY) -- Q2 EBITDA MARGIN 27.5% VS 27.92% (YOY)

SYNGENE INTERNATIONAL: Q2 CONS NET PROFIT 1.06B RUPEES VS 1.16B (YOY)

ZYDUS LIFE: CO RECEIVES ACCEPTABILITY, IN PRINCIPLE, FOR ZYVAC® TCV MAKING IT ELIGIBLE FOR PURCHASE BY UNITED NATIONS PROCUREMENT AGENCIES

ZYDUS LIFE: WHO PREQUALIFIES ZYDUS’S TYPHOID VI CONJUGATE VACCINE, ZYVAC® TCV

BIOCON: AMGENS WILL LAUNCH ITS BIOSIMILAR VERSION OF REGENERONS EYECARE DRUG EYLEA -- EXPECTATION WAS OF BIOCON TO BE AMONGST THE 1ST TO LAUNCH EYLEA- CNBCTV 18

BIOCON: ANALYSTS SAYS AMGENS LAUNCH OF EYLEA MAY LEAD TO EPS CUT FOR BIOCON - CNBCTV18

GLAND PHARMA: CO TO CONSIDER Q2 RESULTS ON NOV 4

KRISHNA INSTITUTE OF MEDICAL SCIENCES: ACQUIRES ADDITIONAL 2.21% STAKE IN SARVEJANA HEALTHCARE -- NOW HOLDS 66.35% OF SARVEJANA HEALTHCARE -- COST FOR ACQUIRING 2.21% EQUITY SHARES IS 368.80M RUPEES

SANOFI: CO AND CD&R PARTNER TO FUEL OPELLA’S AMBITIONS IN CONSUMER HEALTHCARE

SOLARA ACTIVE PHARMA SCIENCES: Q2 EBITDA RUPEES 600.6M VS 310.8M (YOY) -- Q2 EBITDA MARGIN 17.49% VS 7.49% (YOY)

SOLARA ACTIVE PHARMA SCIENCE: CO MD SAYS REAFFIRM OUR FY’25 OUTLOOK FOR REVENUE OF RS 15,000 MN & THE FULL YEAR EBITDA OF RS 2,300 TO RS 2,600 MN & Q425 EXIT QUARTER REVENUE ~RS 4,000 MN & EBITDA OF ~RS 800 TO INR 900 MN WITH EBITDA MARGINS OF 20-22%"

SOLARA ACTIVE PHARMA SCIENCES: Q2 REVENUE 3.5B RUPEES VS 4.25B (YOY)

SOLARA ACTIVE PHARMA SCIENCES: Q2 CONS NET PROFIT 80M RUPEES VS LOSS 171.6M (YOY)

ALEMBIC PHARMA: CO ANNOUNCES USFDA FINAL APPROVAL FOR DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULES USP 120 MG, 180 MG, AND 240 MG -- THIS CAPSULES HAS US SALES OF USD 28.2M

KIMS: CO SAYS MOU WILL COVER NEW PRODUCTS, REPLACEMENTS, AND SERVICES FOR ALL 12 KIMS HOSPITALS AND 4 UPCOMING HOSPITALS

KIMS: CO SIGNS MOU WITH WIPRO GE HEALTHCARE VALUING UPTO RS 700 CRORE.

GRANULES INDIA: CO ANNOUNCES ANDA APPROVAL FOR BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS

MANKIND PHARMA: CO ISSUES SERIES OF COMMERCIAL PAPERS WORTH UPTO 30 BLN, 5 BLN, 15 BLN RUPEES

ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM USFDA FOR FLUDROCORTISONE ACETATE TABLETS USP, 0.1 MG -- FLUDROCORTISONE ACETATE TABLETS HAD ANNUAL SALES OF USD19.9M IN THE UNITED STATES (IQVIA MAT JULY 2024)

SANOFI INDIA: BOARD MEETING ON NOV.7 TO CONSIDER Q2 RESULTS

SHILPA MEDICARE: CO SAYS THE DRUG IS CURRENTLY IN A PHASE 1A CLINICAL TRIAL

SHILPA MEDICARE: CDMO CUSTOMER RECEIVES FAST-TRACK DESIGNATION FOR ITS INVESTIGATIONAL DRUG CANDIDATE

FORTIS HEALTHCARE LTD: RS. 55.74 CRORES NSE BLOCK TRADE; FOR ~ 907834 SHARES, AT RS. 613.95

DR. LAL PATHLABS: BOARD MEETING ON OCT 23 TO CONSIDER Q2 RESULTS

ZYDUS LIFE: EXELIXIS WINS PATENT RULING OVER MSN LABS CABOMETYX COPIES -- MSN WILL NOT BE ABLE TO LAUNCH DRUG ZYDUS WAS MSN PARTNER

STRIDES PHARMA: CO SAYS THE SSA AT PRE-MONEY VALUATION OF USD 1.65B, DELIVERING EMBEDDED VALUE OF RUPEES 663 PER SHARE - AN 82% PREMIUM OVER PREVIOUS VALUE OF RUPEES 364

WOCKHARDT: CO FILES FAST-ACTING INSULIN ASPART INJECTION WITH DCGI; STRENGTHENS COMMITMENT TO DIABETES MANAGEMENT

STRIDES PHARMA: CO ANNOUNCED THAT ITS ASSOCIATE CO ONESOURCE, RECEIVES EQUITY COMMITMENTS OF RUPEES 800 CR FROM MARQUEE INVESTORS AT A PRE-MONEY EQUITY VALUATION OF USD 1.65B (CORRECTION)

ALKEM LABS: CIPLA, CO IN FINAL LAP TO BUY SAHAJANAND MEDICAL TECHNOLOGIES - ECONOMIC TIMES

STRIDES PHARMA: CO ANNOUNCED THAT ITS ASSOCIATE CO ONESOURCE, RECEIVES EQUITY COMMITMENTS OF RUPEES 80 CR FROM MARQUEE INVESTORS AT A PRE-MONEY EQUITY VALUATION OF USD 1.65B

LUPIN: CO LAUNCHES FIRST GENERIC OF PRED FORTE® IN THE UNITED STATES -- US SALES OF USD 198M

DR REDDYS LAB: CO SAYS 3 ADDITIONAL GROUPS OF PLAINTIFFS SOUGHT TO ADD CO AS DEFENDANT IN ALREADY PENDING LAWSUITS -- CO, OTHER DEFENDANTS TO IN RE REVLIMID ANTITRUST ACTION FILED MOTIONS TO DISMISS PLAINTIFFS LAWSUITS

ZYDUS LIFESCIENCES: CO AND ICMR INITIATE A PHASE 2 PROOF-OF-CONCEPT TRIAL OF DESIDUSTAT IN PATIENTS WITH SICKLE CELL DISEASE

MOREPEN LAB: CO SAYS AIMING AT RS 500 CR REVENUE FOR MEDICAL DEVICE BIZ - CNBCTV18

MOREPEN LAB: CO SAYS OPEN TO EXPLORE IPO / PE FUNDING FOR MEDICAL DEVICE BIZ -- GROWING AT 27-28% CAGR IN MEDICAL DEVICES - CNBCTV18

INDOCO REMEDIES: CO INFORMS RECEIPT OF REGULATORY STATUS FROM U.S. FOOD AND DRUG ADMINISTRATION (USFDA), FOR OUR FACILITIES LOCATED AT GOA PLANT -- USFDA HAS DETERMINED THAT THE INSPECTION CLASSIFICATION OF THIS FACILITY REMAINS AS ‘OFFICIAL ACTION INDICATED’ (OAI)

IPCA LABORATORIES: Rs 164.02cr BSE Block Trade; for ~1008521 shares, at Rs 1626.3

JUBILANT PHARMOVA: CO UNIT’S RECTIFICATION APPLICATION LED TO DELETION OF 381.3M RUPEES TAX DEMAND

ZYDUS: CO RECEIVED FINAL APPROVAL FROM USFDA FOR PALIPERIDONE EXTENDED-RELEASE TABLETS, 1.5 MG, 3 MG, 6 MG, AND 9 MG

ALKEM LABS: CO TO CARRY OUT CLINICAL DEVELOPMENT OF "SON-080" IN INDIA TO ENABLE REGULATORY FILING

ALKEM LABORATORIES: CO ENTERS INTO A LICENSING AGREEMENT WITH US-BASED SONNET BIOTHERAPEUTICS TO DEVELOP AND COMMERCIALISE ITS DRUG CANDIDATE FOR DIABETIC PERIPHERAL NEUROPATHY IN INDIA

ASTER DM HEALTHCARE: CO LAUNCHES ADVANCED INTRA-OPERATIVE ELECTRON RADIATION THERAPY AT WHITEFIELD HOSPITAL - HINDU BUSINESSLINE

BIOCON: BIOCON BIOLOGICS GLOBAL RAISES USD 800M VIA ALLOTMENT OF USD NOTES TO STRENGTHEN GLOBAL OPERATIONS

FORTIS HEALTHCARE: CO APPROVED RAISING OF FUNDS WORTH 1500 CR RUPEES VIA ISSUE OF NCDS

SUN PHARMA: BOARD MEETING ON OCTOBER 28 TO CONSIDER Q2 RESULTS

ALEMBIC PHARMA: SUCCESSFULLY COMPLETES USFDA INSPECTION OF ONCOLOGY FORMULATION FACILITY AT PANELAV WITH NO OBSERVATIONS

DR REDDYS LAB: CO SAYS DCGI GIVEN NOD TO COMMENCE PHASE 2 PART OF TRIAL

DR. REDDY’S LABS: CO SUBSIDIARY AURIGENE ONCOLOGY LTD ANNOUNCES PROMISING RESULTS OF PHASE 1 STUDY FOR INDIA’S FIRST TRIAL FOR NOVEL AUTOLOGOUS CAR-T CELL THERAPY FOR MULTIPLE MYELOMA

BIOCON: BIOCON BIOLOGICS’ COMMISSIONED REPORT HIGHLIGHTS PATHWAYS TO INCREASE ADOPTION OF BIOSIMILARS IN LMICS

MAX HEALTHCARE INSTITUTE LTD: RS. 95.05 CRORES NSE BLOCK TRADE; FOR ~ 1002688 SHARES, AT RS. 948.00

MAX HEALTHCARE INSTITUTE LTD: RS. 74.32 CRORES NSE BLOCK TRADE; FOR ~ 803149 SHARES, AT RS. 925.40

APOLLO HOSPITALS ENTERPRISE LTD: Rs. 26.20 Crores NSE Block Trade; for ~ 38529 Shares, at Rs. 6800.00

WOCKHARDT: CO ANNOUNCES ANOTHER BREAKTHROUGH ANTI-BIOTIC: ONCE-A-DAY B-LACTAM ENHANCER WCK 6777 (ERTAPENEM/ZIBDEBACTAM) WITH UNIQUE OUT-PATIENT TREATMENT ADVANTAGE GRANTED FAST TRACK DESIGNATED BY US FDA AND SUCCESSFULLY COMPLETES PHASE I STUDY CONDUCTED BY NATIONAL INSTITUTES OF HEALTH, US

WOCKHARDT: CO ANNOUNCES ANOTHER BREAKTHROUGH ANTI-BIOTIC: ONCE-A-DAY B-LACTAM ENHANCER WCK 6777 (ERTAPENEM/ZIBDEBACTAM) WITH UNIQUE OUT-PATIENT TREATMENT ADVANTAGE GRANTED FAST TRACK DESIGNATED BY US FDA AND SUCCESSFULLY COMPLETES PHASE I STUDY CONDUCTED BY NATIONAL INSTITUTES OF HEALTH, US

NATCO PHARMA: CO AND MYLAN ARE PARTNERED ON THE DEVELOPMENT OF GENERIC OZEMPIC PRODUCTS. THE TERMS OF THE SETTLEMENT ARE CONFIDENTIAL

NATCO PHARMA: CO ANNOUNCES THAT MYLAN PHARMA INC. AND NOVO NORDISK HAVE REACHED A SETTLEMENT OF THE U.S. PATENT LITIGATION RELATED TO GENERIC OZEMPIC (SEMAGLUTIDE)

LUPIN: U.S. FDA HAS COMPLETED A PRE-APPROVAL INSPECTION OF CO BIOTECH FACILITY LOCATED IN PUNE WITH 5 OBSERVATION

FORTIS HEALTHCARE: BOARD MEETING ON OCT 9 TO CONSIDER ISSUE OF NON- CONVERTIBLE DEBENTURES

JUBILANT PHARMOVA: CO SAYS UNIT JBIRSPL TO ACQUIRE 80% EQUITY CAPITAL IN JASMIN FOR UPTO 4.4M EURO -- JASMIN TO ACQUIRE PIERRE FABRE’S R&D CENTRE AT SAINT JULIEN, FRANCE; ENTITY BEING ACQUIRED BELONGS TO DRUG DISCOVERY FOR BIOLOGICS AND ADCS

SYNGENE INTERNATIONAL: BOARD MEETING ON OCT 23 TO CONSIDER Q2 RESULTS

METROPOLIS HEALTH: CO SAYS Q2FY25 REVENUES GREW BY 13% ON (YOY) BASIS -- CO SAYS B2C REVENUES GREW AT 20% ON A (YOY) BASIS ON ACCOUNT OF INDUSTRY-LEADING TESTING CAPABILITIES AND STRONG BRAND APPEAL AMONG END CONSUMERS

MAX HEALTHCARE INSTITUTE LTD: RS. 62.14 CRORES NSE BLOCK TRADE; FOR ~ 664442 SHARES, AT RS. 935.25

INDOCO REMEDIES: CO SAYS CETIRIZINE IS USED FOR RELIEF OF SYMPTOMS OF HAY FEVER AND OTHER ALLERGIC CONDITIONS

INDOCO REMEDIES: CO RECEIVES FINAL ANDA APPROVAL FROM THE USFDA FOR CETIRIZINE HYDROCHLORIDE TABLETS USP, 10 MG (OTC)

AARTI DRUGS: CO SAYS RECEIPT OF GMP CERTIFICATE FROM UK-MHRA FOR MANUFACTURING FACILITY OF UNIT

BIOCON: BOARD MEETING ON OCT 30 TO CONSIDER Q2 RESULTS

SHILPA MEDICARE: CO UNIT GOT CERTIFICATE OF SUITABILITY FROM EDQM FOR API, DESMOPRESSIN

SUVEN LIFE SCIENCES: CO TO PRESENT POSITIVE RESULTS FROM PHASE-2A PROOF-OF-CONCEPT STUDY OF ROPANICANT (SUVN-911) AND UPDATES ON INNOVATION PIPELINE ASSETS AT NEUROSCIENCE 2024, CHICAGO, USA

SUVEN LIFE SCIENCES: CO TO PRESENT POSITIVE RESULTS FROM PHASE-2A PROOF-OF-CONCEPT STUDY OF ROPANICANT (SUVN-911) AND UPDATES ON INNOVATION PIPELINE ASSETS AT NEUROSCIENCE 2024, CHICAGO, USA

APOLLO HOSPITALS ENTERPRISE LTD: Rs. 49.83 Crores NSE Block Trade; for ~ 70343 Shares, at Rs. 7083.90

ERIS LIFESCIENCES LTD: RS. 270.76 CRORES NSE BLOCK TRADE; FOR ~ 2004438 SHARES, AT RS. 1350.80

BIOCON: BIOCON BIOLOGICS REFINANCES USD 1.1B (RUPEES 93,468M) LONG TERM DEBT THROUGH USD BONDS AND NEW SYNDICATED FACILITY

ALEMBIC PHARMA: CO ANNOUNCES USFDA FINAL APPROVAL FOR LAMOTRIGINE EXTENDEDRELEASE TABLETS USP, 200 MG, 250 MG, AND 300 MG -- THIS TABLES HAS US SALES OF USD 163M

DR. REDDY’S LAB: CO SIGNS VOLUNTARY LICENSING AGREEMENT WITH GILEAD SCIENCES TO MANUFACTURE AND COMMERCIALISE LENACAPAVIR IN INDIA AND OTHER COUNTRIES

ZYDUS LIFESCIENCES: ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR ENZALUTAMIDE TABLETS, 40 MG AND 80 MG -- ENZALUTAMIDE TABLETS, 40 MG AND 80 MG HAD ANNUAL SALES OF USD 1417.2M IN THE UNITED STATES (IQVIA MAT JULY 2024)

SMS PHARMA: CO RECEIVES EDQM CERTIFICATION TO SUPPLY IBUPROFEN IN EUROPE

MANKIND PHARMA: INDIA CCI APPROVES ACQUISITION OF BHARAT SERUMS AND VACCINES LTD BY MANKIND PHARMA

JB CHEMICALS: CO SAYS INVESTMENT REQUIRED FOR IV MANUFACTURING EXPANSION AT 494.9M RUPEES -- INVESTMENT REQUIRED FOR MANUFACTURING LINE AT 215.5M RUPEES

JB CHEMICALS: CO APPROVED CAPACITY ADDITION TO IV MANUFACTURING FACILITY AT PANOLI -- CO SAYS ESTABLISHMENT OF DEDICATED MANUFACTURING LINE FOR POVIDONE/IODINE LIQUID, OINTMENT

AUROBINDO PHARMA: CO RECEIVES USFDA APPROVAL FOR CEPHALEXIN TABLETS USP, 250 MG AND 500 MG

GLOBAL HEALTH LTD: RS. 60.88 CRORES NSE BLOCK TRADE; FOR ~ 611907 SHARES, AT RS. 994.95

ZYDUS LIFE: CO RECEIVES USFDA EIR REPORT FOR TRANSDERMAL PATCH MANUFACTURING FACILITY IN AHMEDABAD, CLASSIFIED AS VAI

SUN PHARMA: CO SAYS THE TWO PARTNER COMPANIES WILL SHARE POST-COMMERCIALIZATION ECONOMICS IN ABOUT 45(PHILOGEN):55(SUN PHARMA) RATIO

SUN PHARMA: CO SAYS THE TWO PARTNER COS WILL SHARE POST-COMMERCIALIZATION ECONOMICS IN ABOUT 45 (PHILOGEN): 55 (SUN PHARMA) RATIO

SUN PHARMA: CO SAYS FIBROMUN, AN INNOVATIVE ANTI-CANCER IMMUNOTHERAPY, IS BEING INVESTIGATED IN REGISTRATION TRIALS BY PHILOGEN FOR THE TREATMENT OF SOFT TISSUE SARCOMA AND GLIOBLASTOMA

SUN PHARMA: CO AND PHILOGEN ENTER INTO A GLOBAL EXCLUSIVE COMMERCIALIZATION, LICENSE, AND SUPPLY AGREEMENT FOR COMMERCIALIZING THE SPECIALTY PRODUCT FIBROMUN

KRSNAA DIAGNOSTICS: CO AND MEDIKABAZAAR PARTNER FOR AN UNMATCHED STRATEGIC COLLABORATION TO REVOLUTIONIZE ADVANCED DIAGNOSTICS IN INDIA WITH A PARTNERSHIP WORTH RUPEES 300+ CR, TO MAKE HEALTHCARE MORE ACCESSIBLE FOR ALL

MANKIND PHARMA: CO BOARD APPROVES UP TO RS 10,000 CRORE FUNDRAISING PLAN - MONEYCONTROL

UNICHEM LABORATORIES: PURCHASE FOR $2.7M -- UNIT TO BUY USA GENERICS FORMULATIONS MARKETING/DISTRIBUTION BUSINESS OF BAYSHORE USA; UNITS DEAL FOR $10M

UNICHEM LABORATORIES: CO APPROVED ENTERING INTO AGREEMENTS WITH BAYSHORE PHARMACEUTICALS LLC 30 -- PURCHASE OF RIGHTS, TITLE, INTEREST IN PRODUCT, GOODWILL ASSOCIATED WITH 9 ANDAS OF BAYSHORE USA

PIRAMAL PHARMA SOLUTIONS: CO ANNOUNCES $80M EXPANSION PLAN FOR STERILE INJECTABLES FACILITY IN LEXINGTON, KENTUCKY

KRSNAA DIAGNOSTICS: CO TO ENTER INTO A STRATEGIC COLLABORATION WITH BOSTON IVY HEALTHCARE SOLUTION (P) LIMITED (ALSO KNOWN AS MEDIKABAZAAR) AND UNITED IMAGING HEALTHCARE

AUROBINDO PHARMA: CO SAYS COMPLETION OF US FDA INSPECTION AT UNIT II OF APITORIA PHARMA -- INSPECTION CLOSED WITH 10 OBSERVATIONS

DR REDDYS LAB: CO MADE INVESTMENT OF USD 620M IN DR. REDDY’S LABORATORIES SA, SWITZERLAND

ALEMBIC PHARMACEUTICALS: CO ANNOUNCES USFDA FINAL APPROVAL FOR PALIPERIDONE EXTENDED RELEASE TABLETS, 1.5 MG, 3 MG, 6 MG, AND 9 MG -- PALIPERIDONE EXTENDED-RELEASE TABLETS, 1.5 MG, 3 MG, 6 MG, AND 9 MG HAVE AN ESTIMATED MARKET SIZE OF US$48M FOR TWELVE MONTHS ENDING JUNE 2024 ACCORDING TO IQVIA

MAX HEALTHCARE INSTITUTE LTD: RS. 79.87 CRORES NSE BLOCK TRADE; FOR ~ 802182 SHARES, AT RS. 995.65

ALKEM LABS: CO SAYS ALL PRODUCTS MANUFACTURED AT OUR SITES FOLLOW CURRENT GOOD MANUFACTURING PRACTICES -- SAMPLES OF PRODUCTS MENTIONED IN CDSCO LIST ARE SPURIOUS, NOT MANUFACTURED BY ALKEM

ALKEM LABS: CO DENIES CLAIMS OF PAN-D, CLAVAM 625 BATCHES BEING NOT-OF-STANDARD QUALITY

ALEMBIC PHARMACEUTICALS: CO RECEIVES USFDA FINAL APPROVAL FOR PALIPERIDONE EXTENDEDRELEASE TABLETS, 1.5 MG, 3 MG, 6 MG, AND 9 MG. -- US SALES OF USD 48M

GLAND PHARMA LTD: RS. 100.52 CRORES NSE BLOCK TRADE; FOR ~ 564726 SHARES, AT RS. 1780.00

YATHARTH HOSPITAL: NOIDA & GREATER NOIDA HOSPITAL SHOULD TOUCH OCCUPANCY OF 70-75% - CNBCTV18

ZYDUS LIFE: CO AND CSIR-CENTRAL DRUG RESEARCH INSTITUTE LUCKNOW TO DEVELOP BEST-IN-CLASS DRUG FOR CHRONIC KIDNEY DISEASE INDUCED OSTEOPOROSIS

LUPIN LTD: RS. 67.70 CRORES NSE BLOCK TRADE; FOR ~ 309414 SHARES, AT RS. 2188.15

MAX HEALTHCARE INSTITUTE LTD: Rs. 25.14 Crores NSE Block Trade; for ~ 254375 Shares, at Rs. 988.50

MAX HEALTHCARE: CO ACQUIRES 63.65% STAKE IN JAYPEE HEALTHCARE FOR RUPEES 398 CR IN STRATEGIC DEAL WITH LAKSHDEEP GROUP

TORRENT PHARMA: CO INCORPORATED UNIT NAMELY TORRENT PHARMACEUTICALS CHILE SPA -- ENTITY BEING ACQUIRED BELONGS TO PHARMACEUTICALS SECTOR

SEQUENT SCIENTIFIC: CO, VIYASH LIFE SCIENCES EXPLORE MERGER WORTH RS 7000-8000 CR - ET

TORRENT PHARMA: CO REFUTES CLAIMS OF SHELCAL 500 ALLEGEDLY FAILING CDSCO QUALITY TEST

SUN PHARMA: CO SAYS STUDIES ALSO CONFIRM DOSE OPTIMIZATION, WITH RESULTS DEMONSTRATING GREATER RESPONSE WITH 8 MG TABLETS TWICE-DAILY AS COMPARED TO HIGHER ONCE-DAILY DOSING

SUN PHARMA: CO PRESENTS NEW CLINICAL EFFICACY AND SAFETY DATA IN SEVERE DERMATOLOGICAL CONDITIONS AT THE 2024 EADV CONGRESS -- NEW DATA DEMONSTRATE IMPROVED HAIR SATISFACTION IN MORE THAN 95% OF PATIENTS TAKING DEURUXOLITINIB AND CLINICALLY MEANINGFUL IMPROVEMENTS IN DEPRESSION AND ANXIETY FROM BASELINE TO WEEK 24

JUBILANT PHARMOVA: CO ANNOUNCES COMPLETION OF USFDA AUDIT OF ALLERGY IMMUNOTHERAPY FACILITY & CONTRACT MANUFACTURING FACILITY LOCATED AT SPOKANE, WASHINGTON (USA) -- CO SAYS THE INSPECTION CONCLUDED WITH NO OBSERVATIONS

BIOCON: CO PARTNERS WITH TABUK PHARMACEUTICALS TO COMMERCIALIZE ITS GLUCAGON-LIKE PEPTIDE-1 (GLP -1) PRODUCTS IN THE MIDDLE EAST REGION

KRSNAA DIAGNOSTICS: CO GOT LOI TO COMMISSION RADIOLOGY SERVICES

MAX HEALTHCARE INSTITUTE LTD: Rs. 32.24 Crores NSE Block Trade; for ~ 324349 Shares, at Rs. 994.10

KRSNAA DIAGNOSTICS: CO SAYS WITH THIS PARTNERSHIP CANCER & CARDIAC PATIENTS WILL BE ABLE TO AVAIL COMPLETE SUITE OF DIAGNOSTIC SERVICES 24X7 UNDER ONE ROOF

KRSNAA DIAGNOSTICS: CO ACQUIRES STRATEGIC STAKE IN INDIA’S FIRST PPP DEDICATED FOR CANCER & CARDIAC CARE HOSPITALS

SYNGENE INTERNATIONAL LTD: RS. 61.58 CRORES NSE BLOCK TRADE; FOR ~ 703898 SHARES, AT RS. 874.90

FORTIS: IHH SAYS WILL REVISE OPEN OFFER PRICE HIGHER ONCE NOD COMES IN WILL INCREASE OUR STAKE,EITHER VIA OPEN OFFER OR BY CREEPING ACQUISITION

MAX HEALTHCARE INSTITUTE LTD: RS. 51.85 CRORES NSE BLOCK TRADE; FOR ~ 526465 SHARES, AT RS. 984.80

APOLLO HOSPITALS ENTERPRISE LTD: Rs. 30.39 Crores NSE Block Trade; for ~ 42575 Shares, at Rs. 7137.75

ALKEM LABS: CENTRAL DRUGS STANDARD CONTROL ORGANISATION, HAS FLAGGED 53 DRUG SAMPLES FOR FAILING TO MEET QUALITY STANDARDS - ET NOW

KRSNAA DIAGNOSTICS: CO APPROVED INVESTMENT IN APULKI HEALTHCARE -- CO SHALL ACQUIRE 23.53% OF STAKE IN APULKI -- ENTITY BEING ACQUIRED IS ENGAGED IN ESTABLISHING, OPERATING AND MAINTAINING HOSPITALS, FOCUSING ON ONCOLOGY AND CARDIOLOGY.

ALKEM LAB: ANTACID PAN D, PARACETAMOL, GLIMEPIRIDE AMONG OVER 50 DRUGS FAIL QUALITY TEST - THE NEW INDIAN EXPRESS

AARTI DRUGS: CO RECEIVED 7 INSPECTIONAL OBSERVATIONS IN FORM 483 FROM US FDA

AARTI DRUGS: US FDA INSPECTION WAS AT API MANUFACTURING FACILITY AT TARAPUR -- CO RECEIVED 7 INSPECTIONAL OBSERVATIONS IN FORM 483 FROM US FDA

CIPLA: CO PURCHASE OF 6.9124% EQUITY INTEREST OF JIANGSU XIDI PHARMACEUTICALS HELD IN CIPLA (JIANGSU) -- DEAL FOR RMB 35.8M

MAX HEALTHCARE INSTITUTE LTD: RS. 65.67 CRORES NSE BLOCK TRADE; FOR ~ 659945 SHARES, AT RS. 995.10

GLAND PHARMA LTD: Rs. 36.01 Crores NSE Block Trade; for ~ 194237 Shares, at Rs. 1853.75

MAX HEALTHCARE INSTITUTE LTD: RS. 50.00 CRORES NSE BLOCK TRADE; FOR ~ 502871 SHARES, AT RS. 994.35

JB CHEMICALS: CO FACES A DISAGREEMENT REGARDING THE VALUATION OF KKRS 54% EQUITY STAKE IN THE COMPANY, INDICATING POTENTIAL HURDLES IN NEGOTIATIONS- ETNOW

BIOCON: CO SAYS BIOCON BIOLOGICS ANNOUNCES NEW DERMATOLOGY DATA TO BE PRESENTED AT EADV CONGRESS 2024 -- A PHASE 3 STUDY SUPPORTS THE INTERCHANGEABILITY OF ADALIMUMAB AND ADALIMUMAB-FKJP, AND DEMONSTRATES BIOSIMILARITY BETWEEN BMAB 1200 AND USTEKINUMAB IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS.

GLAND PHARMA LTD: RS. 117.14 CRORES NSE BLOCK TRADE; FOR ~ 628093 SHARES, AT RS. 1865.00

GLAND PHARMA LTD: RS. 117.14 CRORES NSE BLOCK TRADE; FOR ~ 628093 SHARES, AT RS. 1865.00

GLAND PHARMA LTD: RS. 117.14 CRORES NSE BLOCK TRADE; FOR ~ 628093 SHARES, AT RS. 1865.00

LUPIN LTD: RS. 68.26 CRORES NSE BLOCK TRADE; FOR ~ 307212 SHARES, AT RS. 2222.05

GLOBAL HEALTH LTD: Rs. 22.01 Crores NSE Block Trade; for ~ 202920 Shares, at Rs. 1084.80

ASTRAZENECA PHARMA: CO HAS RECEIVED PERMISSION TO IMPORT FOR SALE AND DISTRIBUTION OF DURVALUMAB 120 MG/2.4 ML AND 500 MG/10 ML SOLUTION FOR INFUSION (IMFINZI) FROM THE CENTRAL DRUGS STANDARD CONTROL ORGANISATION

IPCA LABS: BOARD MEETING SCHEDULED FOR SEPTEMBER 30 TO INTEGRATION AND CONSOLIDATION OF THE GENERICS FORMULATIONS BUSINESS IN THE US MARKET

GLOBAL HEALTH LTD: Rs. 26.05 Crores NSE Block Trade; for ~ 232039 Shares, at Rs. 1122.85

UNICHEM LABS: CO TO CONSIDER CONSOLIDATION OF GENERICS FORMULATIONS BUSINESS IN US MARKET

BIOCON: CO SAYS US FDA COMPLETES INSPECTION OF BENGALURU API FACILITY WITH THREE OBSERVATIONS, NO BUSINESS IMPACT EXPECTED

ASTER DM HEALTHCARE: CO UNIT HAS ENTERED INTO LEASE AGREEMENT WITH APARNA CONSTRUCTIONS AND ESTATES PVT LTD FOR SETTING UP NEW ASTER WOMAN AND CHILDREN HOSPITAL IN HYDERABAD

GLENMARK PHARMA: CO SAYS US FDA FINDS NO OBSERVATIONS FOR MFG FACILITY IN AURANGABAD

TORRENT PHARMA: CO ISSUED COMMERCIAL PAPERS FOR 2B RUPEES

ASTRAZENECA PHARMA: CO WILL LAUNCH TREMELIMUMAB (IMJUDO) IN OCTOBER 2024 -- TREMELIMUMAB (IMJUDO) IN COMBINATION WITH DURVALUMAB (IMFINZI) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)

MANKIND PHARMA: CO BOARD APPROVES FUND RAISE WORTH 100B RUPEES VIA ISSUE OF NON-CONVERTIBLE DEBENTURES AND COMMERCIAL PAPERS

GLENMARK PHARMA: CO SAYS U.S. FDA HAS ISSUED FORM 483 WITH ZERO OBSERVATIONS AFTER AN INSPECTION AT THE CO’S FORMULATION MANUFACTURING FACILITY BASED OUT OF CHHATRAPATI SAMBHAJI NAGAR (AURANGABAD), BETWEEN SEPT 09 AND SEPT 20

DR. REDDY’S LABORATORIES: CO SAYS INSPECTION WAS CONDUCTED FROM 16TH SEPT TO 20TH SEPT, 2024; INSPECTION CLOSED WITH ZERO OBSERVATIONS

DR. REDDY’S LABORATORIES: CO SAYS USFDA COMPLETED A ROUTINE GOOD MANUFACTURING PRACTICE (GMP) INSPECTION AT R&D CENTRE (INTEGRATED PRODUCT DEVELOPMENT ORGANISATION OR IPDO) IN BACHUPALLY, HYDERABAD

TORRENT PHARMA: CO SAYS END OF INSPECTION, AGENCY ISSUED FORM FDA 483 WITH ONE OBSERVATION -- FORM FDA 483 WITH ONE OBSERVATION IS PROCEDURAL IN NATURE

TORRENT PHARMA: CO SAYS USFDA CONDUCTED ROUTINE GMP INSPECTION OF FORMULATION MANUFACTURING FACILITY

LUPIN: THE US COURT OF APPEALS FOR THE FEDERAL CIRCUIT HAS VACATED A US DISTRICT COURT JUDGEMENT THAT FAVORED GENERIC COMPANIES IN THE PATENT LITIGATION AROUND GMYRBETRIQ AND REMANDED THE MATTER BACK TO THE DISTRICT COURT. - ETNOW

ZYDUS LIFE: THE US COURT OF APPEALS FOR THE FEDERAL CIRCUIT HAS VACATED A US DISTRICT COURT JUDGEMENT THAT FAVORED GENERIC COMPANIES IN THE PATENT LITIGATION AROUND GMYRBETRIQ AND REMANDED THE MATTER BACK TO THE DISTRICT COURT. - ETNOW

ASTRAZENECA PHARMA: CO TO LAUNCH PALIVIZUMAB (SYNAGIS) IN OCT IN INDIA FOR PREVENTION OF RSV-RELATED SERIOUS LOWER RESPIRATORY TRACT DISEASE IN HIGH-RISK CHILDREN

SHALBY: CO GROUP HAS RECEIVED LICENCE FOR PERFORMING BONE BANK

SUVEN PHARMA: CO NAMES MR. VIVEK SHARMA AS EXECUTIVECHAIRMAN -- VIVEK BRINGS TREMENDOUS CDMO AND LEADERSHIP EXPERTISE TO SUVEN, ACQUIRED ACROSS HIS ROLES AS CEO OF PIRAMAL PHARMA SOLUTIONS (2014-19)

DR. LAL PATHLABS: COS KENYA UNIT HAS BEEN DISSOLVE

DR REDDYS LABORATORIES LTD: RS. 205.53 CRORES NSE BLOCK TRADE; FOR ~ 316201 SHARES, AT RS. 6500.00

SHILPA MEDICARE: CO APPOINTED DR. SRIDEVI KHAMBHAMPATY AS CEO OF SHILPA BIOLOGICALS PVT. LTD, A WHOLLY OWNED SUBSIDIARY OF CO -- PREVIOUSLY WORK AT DR REDDYS, SYNGENE INTERNATIONAL

WOCKHARDT: COS INVESTIGATIONAL DRUG, ZAYNICH CURES COMPLEX CASE OF MENINGITIS CAUSED BY PAN-DRUG RESISTANT SUPER-BUG UNDER COMPASSIONATE USE

P&G: INITIAL FEEDBACK FROM NEW PRODUCT LAUNCHES HAVE BEEN POSITIVE -- FMCG VOLUME GROWTH IS EXPECTED TO BE IN MID-SINGLE DIGIT FOR FY25 -MANEGEMENT MEET

AUROBINDO PHARMA: PURCHASE CONSIDERATION AT 225M RUPEES

AUROBINDO PHARMA: CO ENTERED INTO A BINDING AGREEMENT WITH GLS PHARMA -- SHARES ACQUIRED AT PRICE OF 381.12 RUPEES PER SHARE

ASTER DM HEALTHCARE: THE MERGED ENTITY WILL RANK AMONG THE TOP THREE HOSPITAL CHAINS IN INDIA, IN TERMS OF NUMBER OF BEDS, ALONG WITH APOLLO HOSPITALS AND MANIPAL HOSPITALS- MC

ASTER DM HEALTHCARE: BLACKSTONE’S CARE HOSPITALS IN ADVANCED TALKS FOR MERGER WITH CO - MC

LUPIN: CO ENTERS INTO A NON-EXCLUSIVE PATENT LICENSING AGREEMENT WITH TAKEDA TOCOMMERCIALIZE VONOPRAZAN, A NOVEL GASTROINTESTINAL DRUG IN INDIA

SUVEN LIFE SCIENCES: CO ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE-2A PROOF-OF-CONCEPT SIGNAL DETECTION OPEN LABEL STUDY OF ROPANICANT (SUVN-911) FOR THE TREATMENT OF MODERATE TO SEVERE MAJOR DEPRESSIVE DISORDER (MDD)

AUROBINDO: CO UNIT EUGIA STERILES PRIVATE, RECEIVES EIR FROM US FDA

MANKIND PHARMA: BOARD MEETING ON SEPT 20 TO CONSIDER AND APPROVE RAISING OF FUNDS

BIOCON: COS BIGGEST COMPETITOR COHERUS BIOSCIENCES FACING SUPPLY DISRUPTION IN KEY PRODUCT PEGFILGRASTIM

ZYDUS LIFESCIENCES : CO APPROVED BUSINESS TRANSFER AGREEMENT TO PURCHASE API BUSINESS OF SBL, DEAL OF 84 CR RUPEES

PIRAMAL PHARMA: CO HAS RECEIVED SBTI APPROVAL FOR ITS COMMITMENT TO REDUCE SCOPE 1 AND 2 GHG EMISSIONS BY 42% AND SCOPE 3 BY 25% BY FY 2030

STRIDES PHARMA SCIENCE: CO RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 60 MG -- US SALES OF USD130M

JUBILANT PHARMOVA LTD: Rs. 36.79 Crores NSE Block Trade; for ~ 301179 Shares, at Rs. 1221.50

AUROBINDO PHARMA: AURO STANDS TO GAIN THE MOST WITH 85% PRODUCT OVERLAP OPPORTUNITY SIZEGRANULES FORMULATION SALES TO US AT ~20M/MONTH, ~$250M ANNUALISED

AUROBINDO PHARMA: INVESTEC SAYS ADVERSE IMPACT FROM GRANULES GAGILLAPUR WILL CAUSE MAJOR DISRUPTION & CREATE MORE SUPPLY CHALLENGES IN THE US

DR. REDDYS LAB: CITIUS PHARMACEUTICALS - DR. REDDYS AGREED TO PARTIAL DEFERRAL WITHOUT PENALTY OF MILESTONE PAYMENT BY CITIUS ONCOLOGY INC -- CITIUS PHARMACEUTICALS INC - CO IS GUARANTOR OF OBLIGATIONS OF CITIUS ONCOLOGY, INC UNDER ASSET PURCHASE AGREEMENT - RTRS

LAURUS LABS: CO SAYS USFDA AUDIT COMPLETED TODAY FOR OUR API MANUFACTURING FACILITY AT HYDERABAD (DS-1, IKP KNOWLEDGE PARK, GENOME VALLEY, SHAMEERPET, TELANGANA) WITHOUT ANY 483 OBSERVATION

ARTEMIS MEDICARE SERVICES: CO HAS INFORMED ABOUT THE CAPACITY ADDITION (TOWER-III) IN THE CO’S FLAGSHIP HOSPITAL LOCATED AT GURUGRAM -- CO SAYS CONSTRUCTION OF SAID TOWER III WITH THE CAPACITY TO ACCOMMODATE 180 BEDS HAS BEEN COMPLETED AND IT WILL BE OPERATIONAL IN A GRADED MANNER

ZYDUS LIFESCIENCES: ZYDUS ANNOUNCES EXCLUSIVE LICENSING AND SUPPLY AGREEMENT FOR TWO GADOLINIUM BASED MAGNETIC RESONANCE IMAGING (MRI) INJECTABLE, CONTRAST AGENTS IN THE US -- TOTAL ADDRESSABLE MARKET OPPORTUNITY FOR GADOBUTROL INJECTION IS ESTIMATED AT US$ 120M, AND FOR GADOTERATE MEGLUMINE INJECTION AT US$ 117M IN THE US MARKET (AS PER IQVIA MAT JUL - 2024)

RPG LIFE SCIENCES: CO SAYS EXECUTION OF BINDING AGREEMENT WITH KRSNA DYNASTY; AGREEMENT WORTH 1.45B RUPEES -- AGREEMENT FOR ASSIGNMENT OF SURPLUS VACANT LEASEHOLD LAND

MAX HEALTHCARE: CO STRATEGIC COLLABORATION WITH LAKSHDEEP GROUP FOR REVIVAL AND TURNAROUND OF JAYPEE HEALTHCARE LTD

ALKEM LABS: CO MAY BE A BIDDER FOR JB CHEMICALS - ET

CONCORD BIOTECH: CO TO MEET ANALYSTS/INVESTOR ON 19 SEPTEMBER -- NAME OF THE INVESTORS NOT MENTIONED

GRANULES INDIA: CO SAYS ACTIVELY ADDRESSING THE OBSERVATIONS AND ARE FULLY COMMITTED TO RESOLVING THE ISSUES RAISED. -- AND ARE FULLY COMMITTED IN RESOLVING THE ISSUES

LUPIN: CO SAYS DEAL FOR 105.5M RUPEES -- CO SAYS UPTO 42.61% STAKE IN SUNSURE SOLARPARK TO BE ACQUIRED

LUPIN: CO SIGNED SHARE SUBSCRIPTION & SHAREHOLDERS AGREEMENT WITH SUNSURE SOLARPARK SEVENTEEN -- CO TO MAKE EQUITY INVESTMENT IN SUNSURE SOLARPARK

AUROBINDO: CO GETS APPROVAL FROM USFDA FOR EUGIA STERILES PRIVATE LIMITED, A 100% STEPDOWN SUBSIDIARY.

STRIDES: CO ANNOUNCES APPROVAL FROM EQUITY SHAREHOLDERS AND SECURED CREDITORS FOR CREATION OF ONESOURCE – INDIA’S FIRST SPECIALTY PHARMA CDMO

DR REDDYS LAB: CO ISSUES CLARIFICATION ON CERTAIN ALLEGATIONS PERTAINING TO OUR ENGAGEMENT WITH AGORA ADVISORY, CO ROUTINELY ENGAGE EXTERNAL COACHES TO ENABLE SIGNIFICANT ROLE TRANSITIONS OF LEADERS.

DR REDDYS LAB: CO SAYS ANY SUGGESTION CO WAS TREATED DIFFERENTLY BY SEBI WOULD BE "BASELESS AND MALAFIDE -- CO SAYS CONTINUES TO OPERATE IN COMPLIANCE WITH ALL APPLICABLE LAWS

DR REDDYS LAB: CO SAYS FOR LIMITED PERIOD FROM OCTOBER 2020 TO APRIL 2021, WE ENGAGED SERVICES OF DHAVAL BUCH -- CO SAYS ASSIGNMENT STARTED AND ENDED WELL BEFORE MADHABI BUCHS TERM AS SEBI CHAIRPERSON

DR REDDYS LAB: CO ISSUES CLARIFICATION ON CERTAIN ALLEGATIONS PERTAINING TO OUR ENGAGEMENT WITH AGORA ADVISORY -- CO SAYS ROUTINELY ENGAGE EXTERNAL COACHES TO ENABLE SIGNIFICANT ROLE TRANSITIONS OF LEADERS

JUBILANT PHARMOVA: USFDA DETERMINES INSPECTION CLASSIFICATION OF ‘VOLUNTARY ACTION INDICATED’ FOR THE CONTRACT MANUFACTURING FACILITY AT SPOKANE, WASHINGTON (USA)

ZYDUS LIFESCIENCES: CO ANNOUNCES COMPLETION OF PHASE II(A) CLINICAL TRIAL OF USNOFLAST, A NOVEL ORAL NLRP3 INFLAMMASOME INHIBITOR IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)

UNICHEM LABORATORIES: CO SAYS USFDA HAS NOW CLASSIFIED INSPECTION AS VOLUNTARY ACTION INDICATED

MANKIND PHARMA LTD: RS. 196.28 CRORES NSE BLOCK TRADE; FOR ~ 800552 SHARES, AT RS. 2451.80

AARTI DRUGS: CO TO BUYBACK 6.65 LK SHRS (0.72% EQ) OF THE CO WORTH ₹59.85 CR AT ₹900/SH, BUYBACK OPENS ON SEPT 11 & CLOSES ON SEPT 18

BIOCON: GST COUNCIL - GST RATE ON CANCER DRUGS REDUCED FROM 12% TO 5%; AIMED AT REDUCING THE OVERALL COST OF CANCER TREATMENT SAYS INDIA FIN MIN

CIPLA: GST COUNCIL - GST RATE ON CANCER DRUGS REDUCED FROM 12% TO 5%; AIMED AT REDUCING THE OVERALL COST OF CANCER TREATMENT SAYS INDIA FIN MIN

ZYDUS LIFESCIENCES: GST COUNCIL - GST RATE ON CANCER DRUGS REDUCED FROM 12% TO 5%; AIMED AT REDUCING THE OVERALL COST OF CANCER TREATMENT SAYS INDIA FIN MIN

CIPLA: GST COUNCIL - GST RATE ON CANCER DRUGS REDUCED FROM 12% TO 5%; AIMED AT REDUCING THE OVERALL COST OF CANCER TREATMENT SAYS INDIA FIN MIN

MANKIND PHARMA LTD: RS. 62.39 CRORES NSE BLOCK TRADE; FOR ~ 254692 SHARES, AT RS. 2449.65

WOCKHARDT: CO CLARIFIES ON ALLEGATIONS PERTAINING TO PAYMENT OF RENT BY CAROL INFO SERVICES -- CO SAYS THESE ALLEGATIONS ARE COMPLETELY BASELESS AND MISLEADING

KRISHNA INSTITUTE: CO UNIT ENTERS INTO DEFINITIVE AGREEMENTS WITH SREECHAND SPECIALTY HOSPITALS -- AGREEMENTS TOWARDS LEASE OF LAND, BUILDING WITH OPS, MANAGEMENT OF HOSPITAL

MAX HEALTHCARE INSTITUTE LTD: RS. 54.26 CRORES NSE BLOCK TRADE; FOR ~ 606319 SHARES, AT RS. 894.90

SUN PHARMA: CO & MOEBIUS PLANNING FOR CONFIRMATORY PHASE 3 CLINICAL TRIALS FOR MM-II (LARGE LIPOSOMES OF DPPC AND DMPC) IS UNDERWAY

SUN PHARMA: CO & MOEBIUS ANNOUNCED THAT USFDA HAS GRANTED FAST TRACK DESIGNATION (FTD) TO MM-II FOR THE TREATMENT OF OSTEOARTHRITIS KNEE PAIN.

PFIZER LTD: RS. 69.39 CRORES NSE BLOCK TRADE; FOR ~ 112106 SHARES, AT RS. 6190.05

STRIDES PHARMA: CO RECEIVE USFDA APPROVAL FOR THEOPHYLLINE EXTENDED-RELEASE TABLETS, 300 MG AND 450 MG

DR. REDDY’S LABS: CO RECEIVES USFDA EIR FOR SRIKAKULAM FACILITY, INSPECTION CLASSIFIED AS VOLUNTARY ACTION INDICATED (VAI)

PFIZER LTD: RS. 58.81 CRORES NSE BLOCK TRADE; FOR ~ 95784 SHARES, AT RS. 6140.00

ALEMBIC PHARMA: CO ANNOUNCES USFDA FINAL APPROVAL FOR ALBENDAZOLE TABLETS USP, 200 MG

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA HAS REACHED A SETTLEMENT WITH THE U.S. DEPARTMENT OF JUSTICE, AGREEING TO PAY $25 MILLION OVER FIVE YEARS WITH INTEREST, FOLLOWING THE AUGUST 2023 DEFERRED PROSECUTION AGREEMENT, WITHOUT ADMITTING ADDITIONAL LIABILITY.

APOLLO HOSPITAL: APOLLO HEALTHCO LTD, AN UNLISTED MATERIAL WHOLLY OWNED SUBSIDIARY OF THE CO HAS INCORPORATED ITS WHOLLY OWNED SUBSIDIARY BY THE NAME APOLLO 24/7 INSURANCE SERVICES LTD

LUPIN: CO LAUNCHES MIRABEGRON EXTENDED-RELEASE TABLETS IN THE UNITED STATES -- US SALES OF USD 1.6B

SHILPA MEDICARE: CO ANNOUNCES SUBMISSION OF NDA TO U.S. FDA BY UNICYCIVE - ITS FIRST REGULATORY SUBMISSIONS FROM CDMO PARTNERED PROJECTS

APOLLO HOSPITALS ENTERPRISE: CO SUBSCRIBED TO 343,629 EQUITY SHARES OF ITS SUBSIDIARY APOLLO HEALTHCO LTD FOR RS 399.99 CRORE TO SUPPORT AHLS CAPITAL EXPANSION AND SETTLE PAYABLES.

NATCO PHARMA: NATCO PHARMA (CANADA) INC. ANNOUNCES USD 8 MLN INVESTMENT IN EGENESIS, INC.

FORTIS HEALTHCARE: CO TO SEEK SHAREHOLDERS NOD TO RAISE NCDS WORTH UP TO 15.50B RUPEES

MANKIND PHARMA: CO HAS EXECUTED THE BUSINESS TRANSFER AGREEMENT TO TRANSFER OVER THE COUNTER (OTC) BUSINESS UNDERTAKING OF THE CO AS A GOING CONCERN ON A SLUMP SALE BASIS TO UNIT MANKIND CONSUMER PRODUCTS PVT LTD (MCPPL)

GLAXOSMITHKLINE PHARMA: CO SAYS HAS RECEIVED INCOME TAX ORDER FROM INCOME TAX DEPT UNDER SECTION 143(3) FOR ASSESSMENT YEAR 2022-23, ISSUING INCOME TAX REFUND OF RS 222.23 CR (INCLUDING INTEREST)

ZYDUS LIFESCIENCES: CO ISSUES CLARIFICATION REGARDING RECEIPT OF WARNING LETTER FROM USFDA SAYS AUG 30 USFDA WARNING LETTER DOESNT IMPACT EXISTING PRODUCTS MADE IN JAROD UNIT

ORCHID PHARMA: CO SAYS GOT NO-OBJECTION LETTERS FROM BSE, NSE FOR MERGER OF DHANUKA LABORATORIES WITH CO

NSE INDEX PROVISIONALLY ENDS DOWN 0.04% OR -9.80 POINTS AT 25,268.90

KRISHNA INSTITUTE OF MEDICAL: CO. ANNOUNCES RECORD DATE OF SEPTEMBER 13, 2024 FOR SHARE SPLIT

MANKIND PHARMA LTD: RS. 73.55 CRORES NSE BLOCK TRADE; FOR ~ 301154 SHARES, AT RS. 2442.25

AUROBINDO PHARMA: CO TO STEP UP FOCUS ON BIOSIMILARS, LINES UP A SLEW OF PRODUCTS - BUSINESSLINE

BIOCON: CO SAYS THIS IS BASED ON A PRE-APPROVAL INSPECTION CONDUCTED BY THE AGENCY BETWEEN THE 10TH AND 14TH OF JUNE, 2024, AND NOW ALLOWS CO TO COMMENCE COMMERCIAL SUPPLIES FROM THIS FACILITY TO THE U.S. MARKET

BIOCON: CO HAS RECEIVED AN ESTABLISHMENT INSPECTION REPORT (EIR) FROM USFDA, FOR GREENFIELD API FACILITY (SITE 6), VISAKHAPATNAM, ANDHRA PRADESH

KRISHNA INSTITUTE OF MEDICAL SCIENCES: CO ACQUIRED 100 % EQUITY STAKE OF CHALASANI HOSPITALS -- DEAL FOR 280M RUPEES

FORTIS HEALTHCARE: CO SAYS ACQUISITION BY CO OF ENTIRE STAKE HELD BY PE INVESTORS IN AGILUS DIAGNOSTICS -- CO SAYS FOR ACQUISITION OF STAKE IN ADL RAISING FUNDS THROUGH ISSUANCE OF DEBENTURES

GLAND PHARMA LTD: RS. 176.91 CRORES NSE BLOCK TRADE; FOR ~ 961442 SHARES, AT RS. 1840.00

ZYDUS LIFESCIENCES: CO WILL TAKE ALL NECESSARY STEPS TO WORK WITH USFDA TOWARDS EARLIEST REMEDIATION OF THE ABOVE FACILITY

ZYDUS LIFESCIENCES: CO RECEIVED A WARNING LETTER ISSUED BY THE USFDA

ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM USFDA FOR SCOPOLAMINE TRANSDERMAL SYSTEM -- US SALES OF USD 70M

CIPLA: CO IN AGM SAYS CO HAVE INITIATED PROCESS OF TRANSFER OF PRODUCTS TO OTHER FACILITIES

CIPLA: CO IN AGM SAYS DOING REMEDIATION BOTH IN GOA AND INDORE FACILITIES

ASTER DM HEALTHCARE LTD: Rs. 30.58 Crores NSE Block Trade; for ~ 751431 Shares, at Rs. 406.95

VIMTA LABS: CO SIGNS AGREEMENT TO TRANSFER DIAGNOSTICS BUSINESS TO THYROCARE TECHNOLOGIES FOR RUPEES 70M

PIRAMAL PHARMA: CO APPROVED SUBSCRIPTION OF SHARES WORTH EUR 139.3M OF PIRAMAL DUTCH HOLDINGS N.V.

TORRENT PHARMA: COS INDRAD FACILITY RECEIVES USFDA EIR WITH VOLUNTARY ACTION INDICATED CLASSIFICATION, SUCCESSFULLY CLOSING THE INSPECTION

LUPIN: CO LAUNCHES DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION IN THE UNITED STATES -- DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION (RLD DOXIL® (LIPOSOMAL)) HAD AN ESTIMATED ANNUAL SALES OF USD40.9M IN THE U.S. (IQVIA MAT JUNE 2024)

NATCO PHARMA: CO GETS ANDA APPROVAL FROM USFDA FOR TABRECTA® HAS RECORDED SALES OF USD 126 MILLION

SYNGENE INTERNATIONAL LTD: RS. 59.61 CRORES NSE BLOCK TRADE; FOR ~ 704531 SHARES, AT RS. 846.15

HCG: CO TO MEET GROUP OF INVESTER ON 4 SEP

GLAND PHARMA LTD: RS. 65.12 CRORES NSE BLOCK TRADE; FOR ~ 352760 SHARES, AT RS. 1846.00

BIOCON: CO UNIT SECURES MARKET ENTRY FOR BMAB 1200, A PROPOSED BIOSIMILAR TO STELARA, IN EUROPE, UK, CANADA, AND JAPAN

SHILPA MEDICARE: CO COMPLETES PHASE 1 TRIAL FOR RECOMBINANT HUMAN ALBUMIN (RHA) 20% - RTRS

DIVIS LABORATORIES LTD: RS. 88.38 CRORES NSE BLOCK TRADE; FOR ~ 180681 SHARES, AT RS. 4891.45

ZYDUS LIFE: CO RECEIVES FINAL APPROVAL FROM USFDA FOR AMANTADINE EXTENDED-RELEASE CAPSULES 68.5 MG AND TENTATIVE APPROVAL FOR 137 MG

SUVEN LIFE SCIENCES: CO ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG (IND) AND GRANT OF “STUDY MAY PROCEED LETTER” TO INITIATE PHASE-1 CLINICAL TRIAL OF SUVN-I6107, A TRUE MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR (M1-PAM)

SHILPA MEDICARE: CO MD SAYS THIS SECOND NDA APPROVAL IN THE US MARKET FROM OUR NOVEL INJECTABLE PORTFOLIO OF THE CO

SHILPA MEDICARE: CO GETS USFDA APPROVAL FOR BORTEZOMIB INJECTION NDA 212782

PFIZER LTD: RS. 64.31 CRORES NSE BLOCK TRADE; FOR ~ 109677 SHARES, AT RS. 5864.00

GLOBAL HEALTH: CO CLARIFIES ON MEDIA REPORT - ACQUISITION OF PARAMOUNT TPA, NOT PLANNING TO ACQUIRE STAKE IN PARAMOUNT TPA

ZYDUS LIFESCIENCES: CO SAYS THIS COULD LEAD TO A POTENTIAL COMPETITION AND IMPACT THE SALES AND PROFITS -- CO SAYS THE IMPACT OF THE SAME IS ALREADY FACTORED BY THE CO IN ITS SALES AND OPERATING PROFIT (EBITDA) EXPECTATIONS FOR FY2025

ZYDUS LIFESCIENCES: CO SAYS FURTHER, WE HAVE NOTED THAT AN APPROVAL FOR THE GENERIC PRODUCT IN THE NAME OF GASACOL HD (MESALAMINE 800 MG) OF THE CO, MARKETED IN THE UNITED STATES OF AMERICA, HAS BEEN GIVEN BY THE USFDA TO ANOTHER CO

ZYDUS LIFESCIENCES: CO ISSUES CLARIFICATION SAYS CO HAS GIVEN STATUTORY INTIMATION AND PRESS RELEASE REGARDING ACQUISITION OF 50% STAKE OF STERLING BIOTECH ON AUG 23, 2024 -- CO SAYS WE STRONGLY BELIEVE THAT TODAY’S MATERIAL PRICE MOVEMENT IN THE SHARES OF THE CO IS NOT ATTRIBUTABLE TO THIS EVENT

AMI ORGANICS: CO TO MEET IIFL CARAVAN ON 29 AUGUST

KRSNAA DIAGNOSTIC: CO TO MEET RTL INVESTMENTS ON AUG.27

AARTI DRUGS: CO BOARD OF DIRECTORS HAS SET SEPTEMBER 5 AS THE RECORD DATE FOR THE PLANNED BUYBACK

AARTI DRUGS: CO APPROVED BUYBACK OF SHARES AT 900 RUPEES PER SHARE VIA TENDER OFFER ROUTE

ASTER DM HEALTHCARE: CO SAYS BLACKSTONE MAY OWN 40% HOLDING, CO FOUNDERS MOOPEN FAMILY 20% , TGP 15% - ET NOW

ASTER DM HEALTHCARE: CO SAYS BLACKSTONE TO BE BIGGEST SHAREHOLDER IN MERGED ENTITY -ET NOW

SHILPA MEDICARE: CO PLANS TO SUBMIT THESE PHASE 3 CLINICAL TRIAL FINDINGS AT EARLIEST TO CDSCO

SHILPA MEDICARE: CO SAYS THERE WAS A SUCCESSFUL REDUCTION IN FAT ACCUMULATION IN LIVER

SHILPA MEDICARE: CO ANNOUNCES SUCCESSFUL OUTCOME OF PHASE 3 STUDIES OF SMLNUD07 – NORUDCA

DR. REDDY’S LABORATORIES: CO SAYS THE INSPECTION WAS CONDUCTED FROM AUG19, 2024 TO AUG 23, 2024 -- CO SAYS WE HAVE BEEN ISSUED A FORM 483 WITH THREE OBSERVATIONS, WHICH WE WILL ADDRESS WITHIN THE STIPULATED TIMELINE

DR. REDDY’S LABORATORIES: CO SAYS USFDA TODAY COMPLETED A PRODUCT-SPECIFIC PRE-APPROVAL INSPECTION (PAI) AT OUR FORMULATIONS MANUFACTURING FACILITY (FTO SEZ PU1) IN SRIKAKULAM, ANDHRA PRADESH

FDC: US-FDA INSPECTION AT FACILITY LOCATED AT BADDI -- AUDIT SUCCESSFULLY COMPLETED BY US FDA WITH NO OBSERVATIONS

SUN PHARMA: CO INTRODUCES STARIZO IN INDIA FOR ACUTE BACTERIAL SKIN, SKIN STRUCTURE INFECTIONS

SUN PHARMACEUTICAL INDUSTRIES LTD: RS. 284.42 CRORES NSE BLOCK TRADE; FOR ~ 1612832 SHARES, AT RS. 1763.50

HEALTHCARE GLOBAL: CO CLARIFIES ON NEWS ITEM "C-CARE AND HEALTHCARE GLOBAL ENTERPRISES INK PACT TO DELIVER CANCER CARE SERVICE" -- CO SAYS THIS ARRANGEMENT BETWEEN THE CO AND C-CARE HOSPITALS, AS COVERED IN THE NEWS ITEM, DOES NOT TANTAMOUNT TO A MATERIAL CONTRACT/INFORMATION

ALKEM LABS: RS 487.23CR NSE BLOCK TRADE; FOR ~850000 SHARES, AT RS 5732.15 (PRE-OPEN)

ERIS LIFESCIENCES LTD: RS. 1187.41 CRORES NSE BLOCK TRADE; FOR ~ 9886882 SHARES, AT RS. 1201.00

AARTI DRUGS: CO TO CONSIDER EQUITY SHARE BUYBACK ON AUGUST 26, 2024

ALKEM LABORATORIES: PROMOTER LIKELY TO SELL 0.7% STAKE (8.5 LAKH SHARES) OF ALKEM LABORATORIES VIA BLOCK DEALS -- FLOOR PRICE AT ₹5,616, AT A 3% DISCOUNT TO CMP - CNBCTV18, CITING SOURCES

SUN PHARMA: PHARMAZZ INC. AND SUN PHARMA ENTERED INTO AN AGREEMENT UNDER WHICH SUN PHARMA WILL INVEST UP TO $15M IN PHARMAZZ, INC.

PROCTER & GAMBLE HEALTH: CO HAS RECOMMENDED A FINAL DIVIDEND OF 60 RUPEES PER EQUITY SHARE

PROCTER & GAMBLE HEALTH: CO HAS AN EXCEPTIONAL ITEM OF LOSS 201.9M RUPEES -- Q1 PBT 430.2M RUPEES VS 441.3M (YOY)

PROCTER & GAMBLE HEALTH: Q1 EBITDA 482.5M RUPEES VS 453.4M (YOY) -- Q1 EBITDA MARGIN 17% VS 15.05% (YOY)

PROCTER & GAMBLE HEALTH: Q1 SL NET PROFIT 167.8M RUPEES VS 298.2M (YOY); 465.6M (QOQ) -- Q1 REVENUE 2.84B RUPEES VS 3.01B (YOY); 2.52B (QOQ)

INDOCO REMEDIES: CO RECEIVES FINAL ANDA APPROVAL FROM THE USFDA FOR LOFEXIDINE TABLETS 0.18 MG WITH COMPETITIVE GENERIC THERAPY DESIGNATION -- THIS TABLETS HAS US SALES OF USD 16M

MARKSANS PHARMA: CO UNIT RELONCHEM LIMITED RECEIVES MARKETING AUTHORIZATION FOR ITS PRODUCTS

APOLLO HOSPITALS ENTERPRISE: CCI APPROVES THE PROPOSED COMBINATION INVOLVING ACQUISITION BY ADVENT (THROUGH RASMELI) IN UNIT APOLLO HEALTHCO, ACQUISITION BY APOLLO HEALTHCO IN KEIMED AND MERGER OF KEIMED INTO APOLLO HEALTHCO

MARKSANS PHARMA: CO HAS RECEIVED AN ESTABLISHMENT INSPECTION REPORT (EIR) FROM THE USFDA FOR ITS GOA MANUFACTURING FACILITY, WITH THE INSPECTION BEING SUCCESSFULLY CLOSED AND CLASSIFIED AS "VOLUNTARY ACTION INDICATED" (VAI).

GRANULES INDIA: CO RECEIVES ANDA APPROVAL FOR GLYCOPYRROLATE ORAL SOLUTION

SIGACHI INDUSTRIES: CO INTRODUCES PURECOAT® AND ULTRAMOD™, INNOVATIVE PHARMACEUTICAL FILM COATINGS AND POLYMER BLENDS AIMED AT IMPROVING DRUG DELIVERY, PATIENT COMPLIANCE, AND PRODUCT EFFICACY.

KIMS: RS 184.11CR BSE BLOCK TRADE; FOR ~775758 SHARES, AT RS 2373.28 (PRE-OPEN)

POLY MEDICURE: POLY MEDICURE QIP LAUNCHED, ISSUE SIZE AT ₹1,000 CRORE & INDICATIVE PRICE AT ₹1,850-1,880/SH, AT A 11.6% DISCOUNT TO CMP -- EQUITY ON OFFER IS 5.54% SHARES - CNBCTV18, CITING SOURCES

SEQUENT SCIENTIFIC: CO SAYS MEPRO’S CHEWABLE FORMULATION IS THE FIRST GLOBAL APPROVAL OF ITS KIND BY THE WHO PQ -- ALBENDAZOLE IS A VITAL MEDICATION USED TO TREAT A RANGE OF PARASITIC INFECTIONS, INCLUDING TAPEWORM, ROUNDWORM, AND HOOKWORM INFESTATIONS, AFFECTING MILLIONS GLOBALLY, PARTICULARLY IN LOW AND MIDDLE INCOME COUNTRIES

SEQUENT SCIENTIFIC: CO RECEIVES WHO PREQUALIFICATION APPROVAL FOR ALBENDAZOLE API -- CO SAYS THIS IS IN PARTNERSHIP WITH MEPRO PHARMACEUTICALS, WHO HAVE SUCCESSFULLY DEVELOPED AND COMMERCIALISED THE ALBENDAZOLE CHEWABLE FORMULATION FROM ITS WHO PQ APPROVED PLANT, USING OUR API

STRIDES PHARMA SCIENCE: USFDA HAS DETERMINED THAT THE INSPECTION CLASSIFICATION OF THIS FACILITY IS “VOLUNTARY ACTION INDICATED

STRIDES PHARMA SCIENCE: CO GETS EIR FROM USFDA ON CONTINUED GMP STATUS FOR THE FACILITY IN ALATHUR, CHENNAI

GLENMARK PHARMA: GLENMARK THERAPEUTICS INC., USA LAUNCHES OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION USP, 0.1% (OTC)

CAPLIN POINT LABORATORIES: CO SAYS ANVISA- BRAZIL CONDUCTED AN INSPECTION OF UNIT CAPLIN STERILES’ INJECTABLE AND OPHTHALMIC MANUFACTURING FACILITY LOCATED AT GUMMIDIPOONDI -- CO SAYS THE INSPECTION WAS CONDUCTED BETWEEN AUG 12 AND 16, 2024 AND CONCLUDED WITH ZERO OBSERVATIONS

JUBILANT PHARMOVA: CO TO INVEST UP TO €14.4M OVER 7 YEARS, INCLUDING €4.4M FOR 80% STAKE IN THE NEW COMPANY -- PIERRE FABRE MAY HIRE SERVICES WORTH €7M FROM JUBILANT BIOSYS FOR FIRST 4 YEARS

JUBILANT PHARMOVA: CO UNIT JUBILANT BIOSYS TO ADD DRUG DISCOVERY & PRECLINICAL DEVELOPMENT CAPABILITIES IN BIOLOGICS AND ANTIBODY DRUG CONJUGATE -- CAPABILITIES TO BE ADDED VIA NEW COMPANY INCORPORATED IN FRANCE, WHICH WILL IN TURN ACQUIRE PIERRE FABRES R&D CENTRE IN THE COUNTRY

GLENMARK LIFE SCIENCES: CO GETS REVOCATION LETTER FROM GUJARAT POLLUTION CONTROL BOARD FOR ANKLESHWAR FACILITY

STRIDES PHARMA SCIENCE: CO SAYS UNIT ALTIMA INNOVATIONS, INC, US (ALTIMA), IS DISSOLVED EFFECTIVE AUGUST 13, 2024 -- CO SAYS ALTIMA HAS CEASED TO EXIST AS A CO AND A SUBSIDIARY OF STRIDES GROUP

TARSONS PRODUCTS: Q1 EBITDA 170M RUPEES VS 212M (YOY) -- Q1 EBITDA MARGIN 26.19% VS 33.87% (YOY)

TARSONS PRODUCTS: Q1 SL NET PROFIT 65M RUPEES VS 96M (YOY); 188M (QOQ) -- Q1 REVENUE 649M RUPEES VS 626M (YOY)

GLENMARK PHARMA: Q1 EBITDA 5.9B RUPEES VS 4.4B (YOY) -- Q1 EBITDA MARGIN 18.13% VS 14.40% (YOY)

GLENMARK PHARMA: Q1 CONS NET PROFIT 3.4B RUPEES VS 1.50B (YOY); LOSS 12B (QOQ) -- Q1 REVENUE 32.4B RUPEES VS 30.4B (YOY)

GUFIC BIOSCIENCES: Q1 EBITDA 358M RUPEES VS 355M (YOY) -- Q1 EBITDA MARGIN 17.64% VS 18.19% (YOY)

GUFIC BIOSCIENCES: Q1 REVENUE 2B RUPEES VS 1.95B (YOY)

GUFIC BIOSCIENCES: Q1 SL NET PROFIT 208M RUPEES VS 206M (YOY)

SUN PHARMA: CO SAYS INVESTMENT RESULTING IN MORE THAN 5% HOLDING IN PHARMAZZ INC

SUN PHARMA: CO TO INVEST UPTO $15 MN INVESTMENT IN PHARMAZZ INC

ORCHID PHARMA: COS TARGET FOR A SPECIFIC INITIATIVE IS INR100 CRORES IN THREE TO FOUR YEARS -- CO EXPECTS TO SEE SALES IN INDIA BY MARCH 2027, PENDING PRODUCT REGISTRATION. - CONCALL UPDATE

ORCHID PHARMA: CO IS MAINTAINING ITS GUIDANCE OF RS 100 CR FOR THE AMS DIVISION IN THREE TO FOUR YEARS -- COS LONG-TERM GUIDANCE FOR THE FULL YEAR REMAINS UNCHANGED AT 20% TO 25% GROWTH - CONCALL UPDATE

DISHMAN CARBOGEN AMCIS: Q1 EBITDA 300M RUPEES VS 1.2B (YOY) -- Q1 EBITDA MARGIN 5.73% VS 16.73% (YOY)

DISHMAN CARBOGEN AMCIS: Q1 CONS NET LOSS 776M RUPEES VS 170M (YOY) -- Q1 REVENUE 5.23B RUPEES VS 7.23B (YOY)

MARKSANS PHARMA: Q1 EBITDA 1.3B RUPEES VS 1.02B (YOY) -- Q1 EBITDA MARGIN 21.72% VS 20.4% (YOY)

MARKSANS PHARMA: Q1 CONS NET PROFIT 888M RUPEES VS 686M (YOY); 783M (QOQ) -- Q1 REVENUE 5.9B RUPEES VS 5B (YOY)

APOLLO HOSPITALS ENTERPRISE: Q1 EBITDA 6.75B RUPEES VS 5.1B (YOY); 6.78B EST -- Q1 EBITDA MARGIN 13.27% VS 11.52% (YOY); 13.3% EST

APOLLO HOSPITALS ENTERPRISE: Q1 CONS NET PROFIT 3.05B RUPEES VS 1.66B (YOY); 2.74B EST - 2.5B (QOQ) -- Q1 REVENUE 50.85B RUPEES VS 44B (YOY); 50.78B EST

YATHARTH HOSPITAL & TRAUMA CARE SERVICES: Q1 EBITDA 546M RUPEES VS 414M (YOY) -- Q1 EBITDA MARGIN 25.78% VS 26.8% (YOY)

YATHARTH HOSPITAL & TRAUMA CARE SERVICES: Q1 CONS NET PROFIT 304M RUPEES VS 190M (YOY); 383M (QOQ) -- Q1 REVENUE 2.1B RUPEES VS 1.55B (YOY)

SHALBY: CO ANNOUNCES STRATEGIC CLINICAL TRIAL AGREEMENT WITH MONOGRAM TECHNOLOGIES -- MONOGRAM TECHNOLOGIES IS AN AI-DRIVEN ROBOTICS COMPANY FOCUSED ON IMPROVING HUMAN HEALTH, WITH AN INITIAL FOCUS ON ORTHOPEDIC SURGERY

RAINBOW CHILDRENS MEDICARE: Q1 EBITDA 937.2M RUPEES VS 877M (YOY) -- Q1 EBITDA MARGIN 28.38% VS 30.54% (YOY)

RAINBOW CHILDRENS MEDICARE: Q1 CONS NET PROFIT 395.3M RUPEES VS 410M (YOY); 510M (QOQ) -- Q1 REVENUE 3.3B RUPEES VS 2.87B (YOY); 3.4B (YOY)

IPCA LABORATORIES: Q1 EBITDA 3.92B RUPEES VS 3.07B (YOY) -- Q1 EBITDA MARGIN 18.75% VS 19.38% (YOY)

IPCA LABORATORIES: Q1 REVENUE 21B RUPEES VS 15.9B (YOY)

IPCA LABORATORIES: Q1 CONS NET PROFIT 1.92B RUPEES VS 1.63B (YOY)

CIPLA LTD: RS. 81.32 CRORES NSE BLOCK TRADE; FOR ~ 510688 SHARES, AT RS. 1592.30

ALEMBIC PHARMACEUTICALS: CO ANNOUNCES USFDA DABIGATRAN ETEXILATE CAPSULES, 110 MG.

ERIS LIFESCIENCES LTD: RS. 79.89 CRORES NSE BLOCK TRADE; FOR ~ 665770 SHARES, AT RS. 1200.00

AMI ORGANICS: CO MD SAYS LOOKING AT OUR CURRENT ORDER BOOK, I AM CONFIDENT THAT WE WILL COMFORTABLY MEET OUR 25% GROWTH GUIDANCE FOR THE YEAR - INVESTOR PRESENTATION

CONCORD BIOTECH: CO HAS A ROBUST PIPELINE OF 8-10 NEW PRODUCTS TO BE COMMERCIALIZED OVER THE NEXT 3-4 YEARS -- CO SAYS MANY NEW PRODUCTS PLANNED FOR LAUNCH IN THE COMING YEARS ARE BEING TAKEN UP AT THE LIMBASI FACILITY, WHICH IS SCALING UP AS PLANNED - CONCALL UPDATE

CONCORD BIOTECH: CO EXPECTS THE INJECTABLE PLANT TO START CONTRIBUTING SIGNIFICANTLY OVER THE NEXT TWO TO THREE YEARS, WHICH WOULD SLIGHTLY IMPROVE THE FORMULATION MARGIN - CONCALL UPDATE

CONCORD BIOTECH: CO REITERATES ITS LONG-TERM CAGR GUIDANCE OF REVENUE GROWTH OF 25% OVER A PERIOD OF FIVE YEARS -- CO STANDS BY ITS LONG-TERM GUIDANCE OF 80-20, WHICH IS 20% FORMULATION AND 80% API - CONCALL UPDATE

AMI ORGANICS: CO IS EXPANDING ITS CAPACITY FOR VC, FVC UP TO 2,000 METRIC TONS, BASED ON A LONG-TERM CONTRACT FOR ELECTROLYTE ADDITIVES -- CO IS WORKING ON NEW APPLICATIONS AND OPPORTUNITIES WITH A CDMO IN THE SEMICONDUCTOR SEGMENT IN JAPAN AND KOREA - CONCALL UPDATE

AMI ORGANICS: CO SAYS 16-MEGAWATT SOLAR CAPEX CAPTIVE POWER PLANT PROJECT HAS BEEN INITIATED TO REDUCE CARBON EMISSIONS AND LOWER ENERGY COSTS, WITH COMPLETION EXPECTED BY THE END OF Q2 FY 25 - CONCALL UPDATE

AMI ORGANICS: CO ANTICIPATES SIMILAR STRONG SUBSTANTIAL GROWTH IN THE COMING QUARTER -- CO IS CONFIDENT THAT IT WILL COMFORTABLY MEET ITS 25% GROWTH GUIDANCE FOR THE YEAR BASED ON ITS CURRENT ORDER BOOK - CONCALL UPDATE

ORCHID PHARMA: Q1 EBITDA 325M RUPEES VS 221M (YOY) -- Q1 EBITDA MARGIN 13.29% VS 12.10% (YOY)

ORCHID PHARMA: Q1 CONS NET PROFIT 294M RUPEES VS 94M (YOY); 335M (QOQ) -- Q1 REVENUE 2.4B RUPEES VS 1.83B (YOY)

AMI ORGANICS: Q1 EBITDA 263M RUPEES VS 254M (YOY) -- Q1 EBITDA MARGIN 15.35% VS 17.82% (YOY)

AMI ORGANICS: Q1 SL NET PROFIT 137.2M RUPEES VS 169M (YOY); 321M (QOQ) -- Q1 REVENUE 1.71B RUPEES VS 1.42B (YOY); 2.2B (QOQ)

NATCO PHARMA: CO DECLARED INTERIM DIVIDEND OF RS 3 PER SHARE

NATCO PHARMA: Q1 REVENUE 13.6B RUPEES VS 11.4B (YOY)

NATCO PHARMA: Q1 EBITDA 8.05B RUPEES VS 5.28B (YOY) -- Q1 EBITDA MARGIN 59.06% VS 46.30% (YOY)

NATCO PHARMA: Q1 CONS NET PROFIT 6.7B RUPEES VS 4.2B (YOY)

MOREPEN LABORATORIES: Q1 EBITDA 516M RUPEES VS 261M (YOY) -- Q1 EBITDA MARGIN 11.34% VS 6.51% (YOY)